

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
29 January 2004 (29.01.2004)

PCT

(10) International Publication Number  
**WO 2004/009121 A1**

- (51) International Patent Classification<sup>7</sup>: **A61K 47/16**, 31/4709, A61P 31/14
- (21) International Application Number: PCT/US2003/022434
- (22) International Filing Date: 17 July 2003 (17.07.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/397,280 19 July 2002 (19.07.2002) US
- (71) Applicant: **BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.** [US/US]; 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877-0368 (US).
- (72) Inventors: **CHEN, Shirlynn**; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877-0368 (US). **MEI, Xiaohui**; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877-0368 (US).
- (74) Agents: **RAYMOND, Robert, P.** et al.; Boehringer Ingelheim Corporation, 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877-0368 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
- with international search report
  - before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 2004/009121 A1

(54) Title: PHARMACEUTICAL COMPOSITIONS COMPRISING HEPATITIS C VIRAL PROTEASE INHIBITORS

(57) Abstract: Disclosed are pharmaceutical compositions of hepatitis C viral protease inhibitors having improved bioavailability, and methods of using these compositions for inhibiting the replication of the hepatitis C virus (HCV) and for the treatment of an HCV infection. These compositions include co-solvent systems, lipid based systems, solid dispersions and granulations, and all comprise the hepatitis C viral protease inhibitor, at least one pharmaceutically acceptable amine and optionally one or more additional ingredients.


## PHARMACEUTICAL COMPOSITIONS COMPRISING HEPATITIS C VIRAL PROTEASE INHIBITORS

## FIELD OF THE INVENTION

The present invention relates in general to pharmaceutical compositions of hepatitis C viral protease inhibitors having improved bioavailability, and methods of using these compositions for inhibiting the replication of the hepatitis C virus (HCV) and for the treatment of an HCV infection.

## BACKGROUND OF THE INVENTION

It has recently been discovered that certain peptide analogs are potent and specific inhibitors of hepatitis C virus (HCV) protease. In particular, compounds of the following formula I have been found to be an especially potent class of inhibitors against the NS3 serine protease of HCV:



wherein B is H, a C<sub>6</sub> or C<sub>10</sub> aryl, C<sub>7-16</sub> aralkyl; Het or (lower alkyl)-Het, all of which optionally substituted with C<sub>1-6</sub> alkyl; C<sub>1-6</sub> alkoxy; C<sub>1-6</sub> alkanoyl; hydroxy; hydroxyalkyl; halo; haloalkyl; nitro; cyano; cyanoalkyl; amino optionally substituted with C<sub>1-6</sub> alkyl; amido; or (lower alkyl)amide; or B is an acyl derivative of formula R<sub>4</sub>-C(O)-; a carboxyl derivative formula R<sub>4</sub>-O-C(O)-; an amide derivative of formula R<sub>4</sub>-N(R<sub>5</sub>)-C(O)-; a thioamide derivative of formula R<sub>4</sub>-N(R<sub>5</sub>)-C(S)-; or a sulfonyl derivative of formula R<sub>4</sub>-SO<sub>2</sub> wherein

R<sub>4</sub> is (i) C<sub>1-10</sub> alkyl optionally substituted with carboxyl, C<sub>1-6</sub> alkanoyl, hydroxy, C<sub>1-6</sub> alkoxy, amino optionally mono- or di-substituted with C<sub>1-6</sub> alkyl, amido, or (lower alkyl) amide;

(ii) C<sub>3-7</sub> cycloalkyl, C<sub>3-7</sub> cycloalkoxy, or C<sub>4-10</sub> alkylcycloalkyl, all optionally

- substituted with hydroxy, carboxyl, (C<sub>1-6</sub> alkoxy)carbonyl, amino optionally mono- or di-substituted with C<sub>1-6</sub> alkyl, amido, or (lower alkyl) amide;
- (iii) amino optionally mono- or di-substituted with C<sub>1-6</sub> alkyl; amido; or (lower alkyl)amide;
- 5 (iv) C<sub>6</sub> or C<sub>10</sub> aryl or C<sub>7-16</sub> aralkyl, all optionally substituted with C<sub>1-6</sub> alkyl, hydroxy, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C<sub>1-6</sub> alkyl; or
- (v) Het or (lower alkyl)-Het, both optionally substituted with C<sub>1-6</sub> alkyl, hydroxy, amido, (lower alkyl) amide, or amino optionally mono- or di-substituted with C<sub>1-6</sub> alkyl;
- 10 **R<sub>5</sub>** is H or C<sub>1-6</sub> alkyl;
- with the proviso that when **B** is a carboxyl derivative, an amide derivative or a thioamide derivative, **R<sub>4</sub>** is not a cycloalkoxy;
- Y** is H or C<sub>1-6</sub> alkyl;
- 15 **R<sup>3</sup>** is C<sub>1-8</sub> alkyl, C<sub>3-7</sub> cycloalkyl, or C<sub>4-10</sub> alkylcycloalkyl, all optionally substituted with hydroxy, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> thioalkyl, amido, (lower alkyl)amido, C<sub>6</sub> or C<sub>10</sub> aryl, or C<sub>7-16</sub> aralkyl;
- R<sup>2</sup>** is CH<sub>2</sub>-**R<sub>20</sub>**, NH-**R<sub>20</sub>**, O-**R<sub>20</sub>** or S-**R<sub>20</sub>**, wherein **R<sub>20</sub>** is quinolyl or (lower alkyl)quinolyl, both optionally mono-, di- or tri-substituted with **R<sub>21</sub>**,
- 20 wherein each **R<sub>21</sub>** is independently C<sub>1-6</sub> alkyl; C<sub>1-6</sub> alkoxy; lower thioalkyl; sulfonyl; NO<sub>2</sub>; OH; SH; halo; haloalkyl; amino optionally mono- or di-substituted with C<sub>1-6</sub> alkyl, C<sub>6</sub> or C<sub>10</sub> aryl, C<sub>7-14</sub> aralkyl, Het or (lower alkyl)-Het; amido optionally mono-substituted with C<sub>1-6</sub> alkyl, C<sub>6</sub> or C<sub>10</sub> aryl, C<sub>7-14</sub> aralkyl, Het or (lower alkyl)-Het; carboxyl; carboxy(lower alkyl); C<sub>6</sub> or C<sub>10</sub> aryl, C<sub>7-14</sub> aralkyl or Het, said aryl, aralkyl or Het being
- 25 optionally substituted with **R<sub>22</sub>**;
- wherein **R<sub>22</sub>** is C<sub>1-6</sub> alkyl; C<sub>3-7</sub> cycloalkyl; C<sub>1-6</sub> alkoxy; amino optionally mono- or di-substituted with C<sub>1-6</sub> alkyl or C<sub>3-7</sub>cycloalkyl; sulfonyl; (lower alkyl)sulfonyl; NO<sub>2</sub>; OH; SH; halo; haloalkyl; carboxyl; amide; (lower alkyl)amide; or Het optionally substituted with C<sub>1-6</sub> alkyl;
- 30 **R<sup>1</sup>** is H; C<sub>1-6</sub> alkyl, C<sub>3-7</sub> cycloalkyl, C<sub>2-6</sub> alkenyl, or C<sub>2-6</sub> alkynyl, all optionally substituted with halogen;

or a tautomer thereof.

See, e.g., Llinas-Brunet et al., U.S. Patent No. 6,323,180 B1, which is herein incorporated by reference in its entirety.

5

An HCV serine protease inhibitor such as the compounds of formula I would be expected to be an antiviral agent acting via a novel mechanism, i.e. blockage of a virus-encoded essential function for HCV replication. A drug acting through this mechanism should suppress viral replication of all HCV genotypes and therefore provide tangible benefits to patients with chronic hepatitis C.

10

A common problem among protease inhibitors is that these compounds are lipophilic and have low aqueous solubility. Because of the poor aqueous solubility, conventional solid and liquid pharmaceutical preparations containing these inhibitors may not be absorbed by the patient in a satisfactory manner. Of the various factors that can affect the bioavailability of a drug when administered orally, (which include aqueous solubility, drug absorption through the gastrointestinal tract, dosage strength and first pass effect), aqueous solubility is often found to be among the most important factors. Poorly water soluble compounds often exhibit either erratic or incomplete absorption in the digestive tract, and thus produce a less than desirable response.

15

Representative compounds of formula I have shown poor bioavailability when administered to animals, suggesting that conventional formulations containing these inhibitors may not be absorbed in a satisfactory manner. Thus, there is a need in the art for pharmaceutical compositions of the formula I compounds having improved bioavailability.

20

Examples of "self-emulsifying" formulations of lipophilic compounds include Lipari et al, WO 96/36316, which discloses a self-emulsifying pre-concentrate comprising a lipophilic compound, d-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS) and a lipophilic phase. Gao et al., U.S. Pat. Nos. 6,121,313 discloses a self-emulsifying

25

formulation of a pyranone protease inhibitor comprising the pyranone compound, a mixture of mono- and di-glycerides, one or more solvents and one or more surfactants; and Gao et al, U.S. Pat. No. 6, 231, 887 B1 discloses a self-emulsifying formulation of a pyranone protease inhibitor comprising the pyranone compound, an amine, one or more solvents and one or more surfactants.

Yu et. al U.S. Pat. Nos. 5,360,615 and 5,071,643 disclose the preparation of a solvent system for enhancing the solubility of acidic, basic or amphoteric compounds by partial ionization comprising a mixture of polyethylene glycol, hydroxide or hydrogen ion, and water. Morton et al U.S. Pat. No. 5,376,688 discloses solutions of acidic, basic or amphoteric pharmaceutical agents comprising the pharmaceutical agent, an ionic species and a solvent system. Bhagwat et. al U.S. Pat. Nos. 6,056,977 teaches the use of polysaccharide based matrix for sustained release of a sulfonylurea.

Despite these advances, there continues to be a need in the art for oral pharmaceutical compositions of the compounds of formula I having improved bioavailability.

#### BRIEF SUMMARY OF THE INVENTION


The present invention overcomes the aforementioned problems by providing pharmaceutical compositions of the formula I compounds having improved bioavailability as compared to conventional pharmaceutical formulations.

The pharmaceutical compositions of the present invention cover a wide variety of types of compositions, but all comprise a compound of formula I together with one or more pharmaceutically acceptable amines. The compositions of the present invention may include one or more additional ingredients depending on the type of composition contemplated, e.g., pharmaceutically acceptable bases, solvents, surfactants, oils, polymers, etc., as will be discussed in more detail below. The present invention is also directed to the methods of manufacturing these compositions, as described hereinafter.

In a general embodiment, the pharmaceutical composition of the present invention comprises:

(a) a compound of formula (I):

5



wherein **B** is H, a C<sub>6</sub> or C<sub>10</sub> aryl, C<sub>7-16</sub> aralkyl; Het or (lower alkyl)-Het, all of which  
 10 optionally substituted with C<sub>1-6</sub> alkyl; C<sub>1-6</sub> alkoxy; C<sub>1-6</sub> alkanoyl; hydroxy; hydroxyalkyl;  
 halo; haloalkyl; nitro; cyano; cyanoalkyl; amino optionally substituted with C<sub>1-6</sub> alkyl;  
 amido; or (lower alkyl)amide;

or **B** is an acyl derivative of formula R<sub>4</sub>-C(O)-; a carboxyl derivative formula R<sub>4</sub>-O-C(O)-  
 ; an amide derivative of formula R<sub>4</sub>-N(R<sub>5</sub>)-C(O)-; a thioamide derivative of formula R<sub>4</sub>-  
 15 N(R<sub>5</sub>)-C(S)-; or a sulfonyl derivative of formula R<sub>4</sub>-SO<sub>2</sub> wherein

R<sub>4</sub> is (i) C<sub>1-10</sub> alkyl optionally substituted with carboxyl, C<sub>1-6</sub> alkanoyl, hydroxy,  
 C<sub>1-6</sub> alkoxy, amino optionally mono- or di-substituted with C<sub>1-6</sub> alkyl, amido, or  
 (lower alkyl) amide;

(ii) C<sub>3-7</sub> cycloalkyl, C<sub>3-7</sub> cycloalkoxy, or C<sub>4-10</sub> alkylcycloalkyl, all optionally  
 20 substituted with hydroxy, carboxyl, (C<sub>1-6</sub> alkoxy)carbonyl, amino optionally  
 mono- or di-substituted with C<sub>1-6</sub> alkyl, amido, or (lower alkyl) amide;

(iii) amino optionally mono- or di-substituted with C<sub>1-6</sub> alkyl; amido; or (lower  
 alkyl)amide;

(iv) C<sub>6</sub> or C<sub>10</sub> aryl or C<sub>7-16</sub> aralkyl, all optionally substituted with C<sub>1-6</sub> alkyl,  
 25 hydroxy, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted  
 with C<sub>1-6</sub> alkyl; or

(v) Het or (lower alkyl)-Het, both optionally substituted with C<sub>1-6</sub> alkyl, hydroxy, amido, (lower alkyl) amide, or amino optionally mono- or di-substituted with C<sub>1-6</sub> alkyl;

R<sub>5</sub> is H or C<sub>1-6</sub> alkyl;

5 with the proviso that when B is a carboxyl derivative, an amide derivative or a thioamide derivative, R<sub>4</sub> is not a cycloalkoxy;

Y is H or C<sub>1-6</sub> alkyl;

R<sup>3</sup> is C<sub>1-8</sub> alkyl, C<sub>3-7</sub> cycloalkyl, or C<sub>4-10</sub> alkylcycloalkyl, all optionally substituted with hydroxy, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> thioalkyl, amido, (lower alkyl)amido, C<sub>6</sub> or C<sub>10</sub> aryl, or C<sub>7-16</sub> aralkyl;

10 R<sup>2</sup> is CH<sub>2</sub>-R<sub>20</sub>, NH-R<sub>20</sub>, O-R<sub>20</sub> or S-R<sub>20</sub>, wherein R<sub>20</sub> is quinolyl or (lower alkyl)quinolyl, both optionally mono-, di- or tri-substituted with R<sub>21</sub>,

wherein each R<sub>21</sub> is independently C<sub>1-6</sub> alkyl; C<sub>1-6</sub> alkoxy; lower thioalkyl; sulfonyl;

NO<sub>2</sub>; OH; SH; halo; haloalkyl; amino optionally mono- or di-substituted with C<sub>1-6</sub> alkyl,

15 C<sub>6</sub> or C<sub>10</sub> aryl, C<sub>7-14</sub> aralkyl, Het or (lower alkyl)-Het; amido optionally mono-substituted with C<sub>1-6</sub> alkyl, C<sub>6</sub> or C<sub>10</sub> aryl, C<sub>7-14</sub> aralkyl, Het or (lower alkyl)-Het; carboxyl; carboxy(lower alkyl); C<sub>6</sub> or C<sub>10</sub> aryl, C<sub>7-14</sub> aralkyl or Het, said aryl, aralkyl or Het being optionally substituted with R<sub>22</sub>;

20 wherein R<sub>22</sub> is C<sub>1-6</sub> alkyl; C<sub>3-7</sub> cycloalkyl; C<sub>1-6</sub> alkoxy; amino optionally mono- or di-substituted with C<sub>1-6</sub> alkyl or C<sub>3-7</sub>cycloalkyl; sulfonyl; (lower alkyl)sulfonyl; NO<sub>2</sub>; OH; SH; halo; haloalkyl; carboxyl; amide; (lower alkyl)amide; or Het optionally substituted with C<sub>1-6</sub> alkyl;

R<sup>1</sup> is H; C<sub>1-6</sub> alkyl, C<sub>3-7</sub> cycloalkyl, C<sub>2-6</sub> alkenyl, or C<sub>2-6</sub> alkynyl, all optionally substituted with halogen;

25 or a tautomer thereof;

(b) about 0.1 to 10% by weight of a pharmaceutically acceptable amine or a mixture of pharmaceutically acceptable amines; and

(c) one or more pharmaceutically acceptable oils, carriers or hydrophilic solvents;

30

and when (c) is one or more pharmaceutically acceptable oils, the pharmaceutical

composition further comprises:

(d) optionally one or more pharmaceutically acceptable hydrophilic solvents;

(e) optionally one or more pharmaceutically acceptable polymers;

5 and

(f) optionally one or more pharmaceutically acceptable surfactants;

and when (c) is one or more pharmaceutically acceptable carriers, the pharmaceutical composition further comprises:

10 (d) optionally one or more pharmaceutically acceptable surfactants.

Another important aspect of the present invention involves a method of inhibiting the replication of hepatitis C virus by exposing the virus to a hepatitis C viral NS3 protease-inhibiting amount of a pharmaceutical composition of the present invention.

15

Another aspect of the present invention is the use of the composition of the present invention for the preparation of a medicament for the treatment or prevention of hepatitis C viral infection.

20

Another important aspect of the present invention involves a method of treating a hepatitis C viral infection in a mammal by administering to the mammal in need thereof a therapeutically effective amount of a pharmaceutical composition of the present invention.

25



## DETAILED DESCRIPTION OF THE INVENTION

**Definition of Terms and Conventions Used**

Terms not specifically defined herein should be given the meanings that would be given to them by one of skill in the art in light of the disclosure and the context. As used in the specification, however, unless specified to the contrary, the following terms have the meaning indicated and the following conventions are adhered to.

**A. Chemical and Pharmaceutical Nomenclature, Terms, and Conventions**

In the groups, radicals, or moieties defined below, the number of carbon atoms is often specified preceding the group, for example, C<sub>1-6</sub> alkyl means an alkyl group or radical having 1 to 6 carbon atoms. In general, for groups comprising two or more subgroups, the last named group is the radical attachment point, for example, "thioalkyl" means a monovalent radical of the formula HS-Alk-. Unless otherwise specified below, conventional definitions of terms control and conventional stable atom valences are presumed and achieved in all formulas and groups.

The terms "amide" or "amido" as used herein, either alone or in combination with another substituent, mean a substituent of either of the following formulas: NH<sub>2</sub>C(=O)- or HC(=O)NH-. The terms "substituted amide" and "substituted amido" mean either of the foregoing two groups wherein one or more of the hydrogen atoms are independently replaced.

The terms (lower alkyl)amide or (lower alkyl)amido as used herein, either alone or in combination with another substituent, mean an amide or amido group as defined above wherein one or more of the hydrogen atoms are independently replaced by a lower alkyl group.

The terms "C<sub>1-6</sub> alkyl" or "lower alkyl" as used herein, either alone or in combination with another substituent, means acyclic, straight or branched chain alkyl substituents containing from 1 to six carbon atoms and includes, for example, methyl, ethyl, propyl,

butyl, hexyl, 1-methylethyl, 1-methylpropyl, 2-methylpropyl, and 1,1-dimethylethyl.

The term "C<sub>3-6</sub> cycloalkyl" as used herein, either alone or in combination with another substituent, means a cycloalkyl substituent containing from three to six carbon atoms and  
5 includes cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

The terms "C<sub>1-6</sub> alkoxy" or "lower alkoxy" as used herein, either alone or in combination with another substituent, means the substituent C<sub>1-6</sub> alkyl-O- wherein alkyl is as defined above containing up to six carbon atoms. Alkoxy includes methoxy, ethoxy, propoxy, 1-  
10 methylethoxy, butoxy and 1,1-dimethylethoxy. The latter substituent is known commonly as *tert*-butoxy.

The term "C<sub>3-6</sub> cycloalkoxy" as used herein, either alone or in combination with another substituent, means the substituent C<sub>3-6</sub> cycloalkyl-O- containing from 3 to 6 carbon  
15 atoms.

The term "halo" as used herein means a halogen substituent selected from bromo, chloro, fluoro or iodo.


20 The term "haloalkyl" as used herein means as used herein, either alone or in combination with another substituent, means acyclic, straight or branched chain alkyl substituents having one or more hydrogens substituted for a halogen selected from bromo, chloro, fluoro or iodo.

25 The term "thioalkyl" as used herein means as used herein, either alone or in combination with another substituent, means acyclic, straight or branched chain alkyl substituents containing a thiol (HS) group as a substituent. An example of a thioalkyl group is a thiopropyl, e.g., HS-CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>- is one example of a thiopropyl group.

30 The term "C<sub>6</sub> or C<sub>10</sub> aryl" as used herein, either alone or in combination with another substituent, means either an aromatic monocyclic system containing 6 carbon atoms or an

aromatic bicyclic system containing 10 carbon atoms. For example, aryl includes a phenyl or a naphthyl – ring system.


The term "Het" as used herein, either alone or in combination with another substituent, means a monovalent substituent derived by removal of a hydrogen from a five-, six-, or seven-membered saturated or unsaturated (including aromatic) heterocycle containing carbon atoms and from one to four ring heteroatoms selected from nitrogen, oxygen and sulfur. Examples of suitable heterocycles include: tetrahydrofuran, thiophene, diazepine, isoxazole, piperidine, dioxane, morpholine, pyrimidine or



10

The term "Het " also includes a heterocycle as defined above fused to one or more other rings be it a heterocycle or any other cycle such as a benzene ring. One such examples includes thiazolo[4,5-b]-pyridine. Although generally covered under the term "Het", the term "heteroaryl" as used herein precisely defines an unsaturated heterocycle for which the double bonds form an aromatic system. Suitable example of heteroaromatic system include: quinoline, indole, pyridine,

15



20

The term "oxo" means the double-bonded group (=O) attached as a substituent.

The term "thio" means the double-bonded group (=S) attached as a substituent.

The term "compounds of the invention", and equivalent expressions, are meant to embrace compounds of Formula (I) as herein described, including the tautomers and isomers thereof, where the context so permits. In general, the compounds of the invention and the formulas designating the compounds of the invention are understood to  
5 only include the stable compounds thereof and exclude unstable compounds, even if an unstable compound might be considered to be literally embraced by the compound formula.

The term "stable compound" means a compound that is sufficiently robust to survive  
10 isolation to a useful degree of purity from a reaction mixture and formulation into an efficacious pharmaceutical composition. For example, a compound which would have a "dangling valency" or is a "carbanion" is not a compound contemplated by the invention.

The term "pharmaceutical composition of the invention" and equivalent expressions is  
15 meant to embrace all the various types of pharmaceutical compositions as described hereinafter, unless it is clear from the context that reference is being made to a particular type of pharmaceutical composition within the scope of the present invention.

20 The term "pharmaceutically acceptable" with respect to a substance as used herein means that substance which is, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for the intended use when the substance is used in a pharmaceutical  
25 composition.

The term "semi-solid" means a material that is neither solid (elastic behavior) nor liquid (viscous behavior) and possesses the characteristics of both viscosity and elasticity. Examples of semi-solid materials include gels, ointments, creams, and highly viscous  
30 liquids.

The term "about" means within 20%, preferably within 10%, and more preferably within 5% of a given value or range. For example, "about 10%" means from 8% to 12%, preferably from 9% to 11%, and more preferably from 9.5% to 10.5%. When the term "about" is associated with a range of values, e.g., "about X to Y %", the term "about" is intended to modify both the lower (X) and upper (Y) values of the recited range. For example, "about 0.1 to 10%" is equivalent to "about 0.1% to about 10%".

All percentages recited for amounts of ingredients in the compositions are percentages by weight with respect to the whole composition.

10

#### 15 **B. Isomer Terms and Conventions**

The terms "isomers" or "stereoisomers" mean compounds having the same number and kind of atoms, and hence the same molecular weight, but differing in respect to the arrangement or configuration of the atoms in space. The term includes optical isomers and geometric isomers.

20

The term "optical isomer" means a stable isomer that has at least one chiral atom or restricted rotation giving rise to perpendicular dissymmetric planes (e.g., certain biphenyls, allenes, and spiro compounds) and can rotate plane-polarized light. Because asymmetric centers and other chemical structure exist in the compounds of formula I which may give rise to optical isomerism, the invention contemplates optical isomers and mixtures thereof. The compounds of formula I include asymmetric carbon atoms and may therefore exist as single stereoisomers, racemates, and as mixtures of enantiomers and diastereomers. Typically, such compounds will be prepared as a racemic mixture. If desired, however, such compounds can be prepared or isolated as pure optical isomers, i.e., as individual enantiomers or diastereomers, or as stereoisomer-enriched mixtures. Individual stereoisomers of compounds are prepared by synthesis from optically active starting materials containing the desired chiral centers or by preparation of mixtures of enantiomeric products followed by separation, such as conversion to a mixture of diastereomers followed by separation or recrystallization, chromatographic techniques,

25  
30

use of chiral resolving agents, or direct separation of the enantiomers on chiral chromatographic columns. Starting compounds of particular stereochemistry are either commercially available or are made by the methods described below and resolved by techniques well-known in the art.

5

The term "enantiomers" means a pair of optical isomers that are non-superimposable mirror images of each other.

The term "diastereoisomers" means optical isomers which are not mirror images of each other.

10

The term "racemic mixture" means a mixture containing equal parts of individual enantiomers.

The term "non-racemic mixture" means a mixture containing unequal parts of individual enantiomers or stereoisomers.

15

The term "geometrical isomer" means a stable isomer which results from restricted freedom of rotation about double bonds (e.g., *cis*-2-butene and *trans*-2-butene) or in a cyclic structure (e.g., *cis*-1,3-dichlorocyclobutane and *trans*-1,3-dichlorocyclobutane). Because carbon-carbon double (olefinic) bonds, cyclic structures, and the like may be present in the compounds of formula I, the invention contemplates each of the various stable geometric isomers and mixtures thereof resulting from the arrangement of substituents around these double bonds and in these cyclic structures. The substituents and the isomers are designated using the *cis/trans* convention.

20

25

Some of the compounds of formula I can exist in more than one tautomeric form. As mentioned above, the compounds of formula I include all such tautomers.

In general, all tautomeric forms and isomeric forms and mixtures, whether individual geometric isomers or optical isomers or racemic or non-racemic mixtures of isomers, of a

30

chemical structure or compound is intended, unless the specific stereochemistry or isomeric form is specifically indicated in the compound name or structure.

### **C. Pharmaceutical Administration and Treatment Terms and Conventions**

5 The term "patient" includes both human and non-human mammals.

The term "therapeutically effective amount" means an amount of a compound according to the invention which, when administered to a patient in need thereof, is sufficient to effect treatment of a hepatitis C viral infection. Further guidance with respect to  
10 determining suitable dosage levels for such effective treatment may be found in the "Methods of Therapeutic Use" section below. Such a therapeutically effective amount can be determined routinely by one of ordinary skill in the art having regard to their own knowledge, the prior art, and this disclosure.

15 The terms "treating" or "treatment" mean the treatment of a hepatitis C viral infection in a patient, and include:


- (i) preventing the hepatitis C viral infection from occurring in a patient, in particular, when such patient is predisposed to such disease-state but has not yet been diagnosed as having it;
- 20 (ii) inhibiting or ameliorating the hepatitis C viral infection, i.e., arresting or slowing its development; or
- (iii) relieving the hepatitis C viral infection, i.e., causing regression or cure of the disease-state.

### **25 Preferred Embodiments of the Invention**

#### **I. Co-Solvent System**

A first embodiment which we refer to herein as the "co-solvent" system is directed to a  
30 pharmaceutical composition comprising:

(a) a compound of formula (I):



- 5 wherein **B** is H, a C<sub>6</sub> or C<sub>10</sub> aryl, C<sub>7-16</sub> aralkyl; Het or (lower alkyl)-Het, all of which optionally substituted with C<sub>1-6</sub> alkyl; C<sub>1-6</sub> alkoxy; C<sub>1-6</sub> alkanoyl; hydroxy; hydroxyalkyl; halo; haloalkyl; nitro; cyano; cyanoalkyl; amino optionally substituted with C<sub>1-6</sub> alkyl; amido; or (lower alkyl)amide;
- or **B** is an acyl derivative of formula R<sub>4</sub>-C(O)-; a carboxyl derivative formula R<sub>4</sub>-O-C(O)-
- 10 ; an amide derivative of formula R<sub>4</sub>-N(R<sub>5</sub>)-C(O)-; a thioamide derivative of formula R<sub>4</sub>-N(R<sub>5</sub>)-C(S)-; or a sulfonyl derivative of formula R<sub>4</sub>-SO<sub>2</sub> wherein
- R<sub>4</sub> is (i) C<sub>1-10</sub> alkyl optionally substituted with carboxyl, C<sub>1-6</sub> alkanoyl, hydroxy, C<sub>1-6</sub> alkoxy, amino optionally mono- or di-substituted with C<sub>1-6</sub> alkyl, amido, or (lower alkyl) amide;
- 15 (ii) C<sub>3-7</sub> cycloalkyl; C<sub>3-7</sub> cycloalkoxy, or C<sub>4-10</sub> alkylcycloalkyl, all optionally substituted with hydroxy, carboxyl, (C<sub>1-6</sub> alkoxy)carbonyl, amino optionally mono- or di-substituted with C<sub>1-6</sub> alkyl, amido, or (lower alkyl) amide;
- (iii) amino optionally mono- or di-substituted with C<sub>1-6</sub> alkyl; amido; or (lower alkyl)amide;
- 20 (iv) C<sub>6</sub> or C<sub>10</sub> aryl or C<sub>7-16</sub> aralkyl, all optionally substituted with C<sub>1-6</sub> alkyl, hydroxy, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C<sub>1-6</sub> alkyl; or
- (v) Het or (lower alkyl)-Het, both optionally substituted with C<sub>1-6</sub> alkyl, hydroxy, amido, (lower alkyl) amide, or amino optionally mono- or di-substituted with C<sub>1-6</sub>
- 25 alkyl;



$R_5$  is H or  $C_{1-6}$  alkyl;

with the proviso that when **B** is a carboxyl derivative, an amide derivative or a thioamide derivative,  $R_4$  is not a cycloalkoxy;

$Y$  is H or  $C_{1-6}$  alkyl;

- 5  $R^3$  is  $C_{1-8}$  alkyl,  $C_{3-7}$  cycloalkyl, or  $C_{4-10}$  alkylcycloalkyl, all optionally substituted with hydroxy,  $C_{1-6}$  alkoxy,  $C_{1-6}$  thioalkyl, amido, (lower alkyl)amido,  $C_6$  or  $C_{10}$  aryl, or  $C_{7-16}$  aralkyl;

$R^2$  is  $CH_2-R_{20}$ ,  $NH-R_{20}$ ,  $O-R_{20}$  or  $S-R_{20}$ , wherein  $R_{20}$  is quinolyl or (lower alkyl)quinolyl, both optionally mono-, di- or tri-substituted with  $R_{21}$ ,

- 10 wherein each  $R_{21}$  is independently  $C_{1-6}$  alkyl;  $C_{1-6}$  alkoxy; lower thioalkyl; sulfonyl;  $NO_2$ ; OH; SH; halo; haloalkyl; amino optionally mono- or di-substituted with  $C_{1-6}$  alkyl,  $C_6$  or  $C_{10}$  aryl,  $C_{7-14}$  aralkyl, Het or (lower alkyl)-Het; amido optionally mono-substituted with  $C_{1-6}$  alkyl,  $C_6$  or  $C_{10}$  aryl,  $C_{7-14}$  aralkyl, Het or (lower alkyl)-Het; carboxyl; carboxy(lower alkyl);  $C_6$  or  $C_{10}$  aryl,  $C_{7-14}$  aralkyl or Het, said aryl, aralkyl or Het being  
15 optionally substituted with  $R_{22}$ ;

wherein  $R_{22}$  is  $C_{1-6}$  alkyl;  $C_{3-7}$  cycloalkyl;  $C_{1-6}$  alkoxy; amino optionally mono- or di-substituted with  $C_{1-6}$  alkyl or  $C_{3-7}$  cycloalkyl; sulfonyl; (lower alkyl)sulfonyl;  $NO_2$ ; OH; SH; halo; haloalkyl; carboxyl; amide; (lower alkyl)amide; or Het optionally substituted with  $C_{1-6}$  alkyl;

- 20  $R^1$  is H;  $C_{1-6}$  alkyl,  $C_{3-7}$  cycloalkyl,  $C_{2-6}$  alkenyl, or  $C_{2-6}$  alkynyl, all optionally substituted with halogen;  
or a tautomer thereof;

- (b) about 0.1 to 10% by weight of a pharmaceutically acceptable amine or a mixture  
25 of pharmaceutically acceptable amines; and

(c) one or more pharmaceutically acceptable hydrophilic solvents.

The pharmaceutical composition may optionally further contain one or more pharmaceutically acceptable bases.

30

The amount of the active ingredient (formula (I) compound) that may be present in the

co-solvent system composition may vary widely or be adjusted widely depending on the intended route of administration, the potency of the particular active ingredient being used, the severity of the hepatitis C viral infection and the required concentration. In a particular embodiment, the compound of formula (I) is present in the co-solvent system composition in an amount of from about 1% to 50% by weight, preferably from about 5% to 30% by weight, more preferably from about 5% to 15% by weight.

Pharmaceutically acceptable amines useful in the composition include, for example, C<sub>1-6</sub> alkylamine, di-(C<sub>1-6</sub> alkyl)-amine or tri-(C<sub>1-6</sub> alkyl)-amine, wherein one or more alkyl groups thereof may be optionally substituted by one or more hydroxy groups, or C<sub>1-6</sub> alkylenediamine, a basic amino acid or choline hydroxide, or mixtures thereof. Specific amines include ethanolamine, diethanolamine, triethanolamine, tris(hydroxymethyl)aminomethane, ethylenediamine or dimethylaminoethanol, or mixtures thereof. A preferred amine is tris(hydroxymethyl)aminomethane (also called "Tris" or "Tromethamine"). The amine is present in an amount of about 0.1 to 10% by weight, more preferably in an amount of from about 0.5% to 7% by weight; even more preferably from about 0.5% to 5% by weight.

Pharmaceutically acceptable hydrophilic solvents useful in the composition include, for example, propylene glycol, polypropylene glycol; polyethylene glycol (e.g. PEG 400), glycerol, ethanol, dimethyl isosorbide, glycofurol, propylene carbonate, dimethyl acetamide, water, or mixtures thereof; preferably, propylene glycol, polyethylene glycol, ethanol, water, or mixtures thereof. A preferred solvent is a mixture of propylene glycol, ethanol and water. The amount of solvent(s) in the composition may vary over a wide range and the optimum amount for a particular composition will depend on the type and amount of other the other ingredients in the composition as can be easily determined by the skilled worker. In general, however, the solvent(s) are present in an amount of from about 40% to 99% by weight, preferably from about 80% to 99% by weight, more preferably, from about 80% to 90% by weight.

Pharmaceutically acceptable bases useful in the composition include, for example,

potassium hydroxide, sodium hydroxide, sodium hydrogen carbonate, aluminum hydroxide, calcium carbonate, magnesium hydroxide, magnesium aluminum silicate, synthetic aluminum silicate, synthetic hydrotalcite, magnesium aluminum hydroxide. Also suitable are bases which are salts of a pharmaceutically acceptable acid, such as

5 acetic acid, acrylic acid, adipic acid, alginic acid, alkanesulfonic acid, amino acids, ascorbic acid, benzoic acid, boric acid, butyric acid, carbonic acid, citric acid, fatty acids, formic acid, fumaric acid, gluconic acid, hydroquinosulfonic acid, isoascorbic acid, lactic acid, maleic acid, oxalic acid, para-bromophenylsulfonic acid, propionic acid, p-toluenesulfonic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid,

10 thioglycolic acid, toluenesulfonic acid, uric acid, and the like. Salts of polyprotic acids, such as sodium phosphate, disodium hydrogen phosphate, and sodium dihydrogen phosphate can also be used. When the base is a salt, the cation can be any convenient and pharmaceutically acceptable cation, such as ammonium, alkali metals, alkaline earth metals, and the like. Preferred cations include sodium, potassium, lithium, magnesium,

15 calcium and ammonium. Some preferred bases include sodium hydroxide, potassium hydroxide, sodium hydrogen carbonate, aluminum hydroxide, magnesium hydroxide and magnesium aluminum hydroxide. When used in the composition, the pharmaceutically acceptable base is preferably present in the composition in an amount of from about 0.1 to 10% by weight, for example about 0.1 to 5% by weight, for example about 0.1 to 3%

20 by weight.

A particular embodiment of the co-solvent system is directed to a pharmaceutical composition, comprising:

- (a) about 5% to 30% by weight of a compound of formula (I);
- 25 (b) about 0.5% to 7% by weight of a pharmaceutically acceptable amine; and
- (c) about 40% to 99% by weight of pharmaceutically acceptable hydrophilic solvent.

A further particular embodiment of the co-solvent system is directed to a pharmaceutical

30 composition, comprising:

- (a) about 5% to 15% by weight of a compound of formula (I);

- (b) about 0.5% to 5% by weight of a pharmaceutically acceptable amine; and
- (c) about 80% to 99% by weight of pharmaceutically acceptable hydrophilic solvent.

5 A further particular embodiment of the co-solvent system is directed to a pharmaceutical composition, comprising:

- (a) about 5% to 15% by weight of a compound of formula (I);
  - (b) about 0.5% to 5% by weight of tris(hydroxymethyl)aminomethane; and
  - (c) about 80% to 90% by weight of a mixture of propylene glycol, ethanol and
- 10 water.

The co-solvent system composition may be prepared in a conventional manner, for example, by dissolving the amine(s) in the pharmaceutically acceptable solvent(s), adding the compound of formula (I) to the resulting solution and then mixing the resulting

15 solution until all or substantially all of the compound of formula I is solubilized in the solution. This method of preparing the composition constitutes another aspect of the present invention. The resulting solution is then formulated into the desired dosage form such as topical, parenteral and in particular oral dosage forms.

20


## II. Lipid-Based System

A second embodiment which we refer to herein as the "Lipid-Based System" is directed to a pharmaceutical composition comprising:

25

- (a) a compound of formula (I):

30



wherein **B** is H, a C<sub>6</sub> or C<sub>10</sub> aryl, C<sub>7-16</sub> aralkyl; Het or (lower alkyl)-Het, all of which optionally substituted with C<sub>1-6</sub> alkyl; C<sub>1-6</sub> alkoxy; C<sub>1-6</sub> alkanoyl; hydroxy; hydroxyalkyl; halo; haloalkyl; nitro; cyano; cyanoalkyl; amino optionally substituted with C<sub>1-6</sub> alkyl; amido; or (lower alkyl)amide;

or **B** is an acyl derivative of formula R<sub>4</sub>-C(O)-; a carboxyl derivative formula R<sub>4</sub>-O-C(O)-; an amide derivative of formula R<sub>4</sub>-N(R<sub>5</sub>)-C(O)-; a thioamide derivative of formula R<sub>4</sub>-N(R<sub>5</sub>)-C(S)-; or a sulfonyl derivative of formula R<sub>4</sub>-SO<sub>2</sub> wherein

R<sub>4</sub> is (i) C<sub>1-10</sub> alkyl optionally substituted with carboxyl, C<sub>1-6</sub> alkanoyl, hydroxy, C<sub>1-6</sub> alkoxy, amino optionally mono- or di-substituted with C<sub>1-6</sub> alkyl, amido, or (lower alkyl) amide;

(ii) C<sub>3-7</sub> cycloalkyl, C<sub>3-7</sub> cycloalkoxy, or C<sub>4-10</sub> alkylcycloalkyl, all optionally substituted with hydroxy, carboxyl, (C<sub>1-6</sub> alkoxy)carbonyl, amino optionally mono- or di-substituted with C<sub>1-6</sub> alkyl, amido, or (lower alkyl) amide;

(iii) amino optionally mono- or di-substituted with C<sub>1-6</sub> alkyl; amido; or (lower alkyl)amide;

(iv) C<sub>6</sub> or C<sub>10</sub> aryl or C<sub>7-16</sub> aralkyl, all optionally substituted with C<sub>1-6</sub> alkyl, hydroxy, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C<sub>1-6</sub> alkyl; or

(v) Het or (lower alkyl)-Het, both optionally substituted with C<sub>1-6</sub> alkyl, hydroxy, amido, (lower alkyl) amide, or amino optionally mono- or di-substituted with C<sub>1-6</sub> alkyl;

R<sub>5</sub> is H or C<sub>1-6</sub> alkyl;

with the proviso that when **B** is a carboxyl derivative, an amide derivative or a thioamide derivative, R<sub>4</sub> is not a cycloalkoxy;

Y is H or C<sub>1-6</sub> alkyl;

R<sup>3</sup> is C<sub>1-8</sub> alkyl, C<sub>3-7</sub> cycloalkyl, or C<sub>4-10</sub> alkylcycloalkyl, all optionally substituted with hydroxy, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> thioalkyl, amido, (lower alkyl)amido, C<sub>6</sub> or C<sub>10</sub> aryl, or C<sub>7-16</sub> aralkyl;

- 5 R<sup>2</sup> is CH<sub>2</sub>-R<sub>20</sub>, NH-R<sub>20</sub>, O-R<sub>20</sub> or S-R<sub>20</sub>, wherein R<sub>20</sub> is quinolyl or (lower alkyl)quinolyl, both optionally mono-, di- or tri-substituted with R<sub>21</sub>,  
wherein each R<sub>21</sub> is independently C<sub>1-6</sub> alkyl; C<sub>1-6</sub> alkoxy; lower thioalkyl; sulfonyl; NO<sub>2</sub>; OH; SH; halo; haloalkyl; amino optionally mono- or di-substituted with C<sub>1-6</sub> alkyl, C<sub>6</sub> or C<sub>10</sub> aryl, C<sub>7-14</sub> aralkyl, Het or (lower alkyl)-Het; amido optionally mono-substituted  
10 with C<sub>1-6</sub> alkyl, C<sub>6</sub> or C<sub>10</sub> aryl, C<sub>7-14</sub> aralkyl, Het or (lower alkyl)-Het; carboxyl; carboxy(lower alkyl); C<sub>6</sub> or C<sub>10</sub> aryl, C<sub>7-14</sub> aralkyl or Het, said aryl, aralkyl or Het being optionally substituted with R<sub>22</sub>;

- wherein R<sub>22</sub> is C<sub>1-6</sub> alkyl; C<sub>3-7</sub> cycloalkyl; C<sub>1-6</sub> alkoxy; amino optionally mono- or di-substituted with C<sub>1-6</sub> alkyl or C<sub>3-7</sub>cycloalkyl; sulfonyl; (lower  
15 alkyl)sulfonyl; NO<sub>2</sub>; OH; SH; halo; haloalkyl; carboxyl; amide; (lower alkyl)amide; or Het optionally substituted with C<sub>1-6</sub> alkyl;

R<sup>1</sup> is H; C<sub>1-6</sub> alkyl, C<sub>3-7</sub> cycloalkyl, C<sub>2-6</sub> alkenyl, or C<sub>2-6</sub> alkynyl, all optionally substituted with halogen;  
or a tautomer thereof;

20

- (b) about 0.1 to 10% by weight of a pharmaceutically acceptable amine or a mixture of pharmaceutically acceptable amines;

- (c) one or more pharmaceutically acceptable oils;

25

- (d) optionally one or more pharmaceutically acceptable hydrophilic solvents;

- (e) optionally one or more pharmaceutically acceptable polymers;

and

30

- (f) optionally one or more pharmaceutically acceptable surfactants.

The composition may optionally further contain one or more pharmaceutically acceptable bases.

- 5 The amount of the active ingredient (formula (I) compound) that may be present in the lipid-based system composition may vary widely or be adjusted widely depending on the intended route of administration, the potency of the particular active ingredient being used, the severity of the hepatitis C viral infection and the required concentration. In a particular embodiment, the compound of formula (I) is present in the lipid-based system  
10 in an amount of from about 1% to 50% by weight, preferably from about 5% to 30% by weight, more preferably from about 10% to 20% by weight.

Pharmaceutically acceptable amines useful in the composition include, for example, C<sub>1-6</sub> alkylamine, di-(C<sub>1-6</sub> alkyl)-amine or tri-(C<sub>1-6</sub> alkyl)-amine, wherein one or more alkyl  
15 groups thereof may be optionally substituted by one or more hydroxy groups, or C<sub>1-6</sub> alkylenediamine, a basic amino acid or choline hydroxide, or mixtures thereof. Specific amines include ethanolamine, diethanolamine, triethanolamine, tris(hydroxymethyl)aminomethane, ethylenediamine or dimethylaminoethanol, or mixtures thereof. A preferred amine is tris(hydroxymethyl)aminomethane (also called  
20 "Tris"; and "tromethamine"). The amine is present in an amount of about 0.1 to 10% by weight, more preferably in an amount of from about 0.1% to 7% by weight; even more preferably from about 0.1% to 5% by weight.

Pharmaceutically acceptable bases useful in the composition include, for example,  
25 potassium hydroxide, sodium hydroxide, sodium hydrogen carbonate, aluminum hydroxide, calcium carbonate, magnesium hydroxide, magnesium aluminum silicate, synthetic aluminum silicate, synthetic hydrotalcite, magnesium aluminum hydroxide. Also suitable are bases which are salts of a pharmaceutically acceptable acid, such as acetic acid, acrylic acid, adipic acid, alginic acid, alkanesulfonic acid, amino acids,  
30 ascorbic acid, benzoic acid, boric acid, butyric acid, carbonic acid, citric acid, fatty acids, formic acid, fumaric acid, gluconic acid, hydroquinosulfonic acid, isoascorbic acid, lactic

acid, maleic acid, oxalic acid, para-bromophenylsulfonic acid, propionic acid, p-toluenesulfonic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, thioglycolic acid, toluenesulfonic acid, uric acid, and the like. Salts of polyprotic acids, such as sodium phosphate, disodium hydrogen phosphate, and sodium dihydrogen phosphate can also be used. When the base is a salt, the cation can be any convenient and pharmaceutically acceptable cation, such as ammonium, alkali metals, alkaline earth metals, and the like. Preferred cations include sodium, potassium, lithium, magnesium, calcium and ammonium. Some preferred bases include sodium hydroxide, potassium hydroxide, sodium hydrogen carbonate, aluminum hydroxide, magnesium hydroxide and magnesium aluminum hydroxide. When used in the composition, the pharmaceutically acceptable base is present in the composition in an amount of from about 0.1 to 10% by weight, for example about 0.1 to 5% by weight, for example about 0.1 to 3% by weight.

Pharmaceutically acceptable oils useful in the composition includes a broad spectrum of water-immiscible materials such as, for example, medium or long chain mono-, di- or triglycerides, vegetable oils such as soybean oil, avocado oil, squalene oil, sesame oil, olive oil, canola oil, corn oil, rapeseed oil, safflower oil, and sunflower oil, fish oils, flavored oils, water insoluble vitamins, fatty acids, and mixtures thereof. More preferred oils include mono-, di- or triglycerides of caprylic fatty acids; mono-, di- or triglycerides of capric fatty acids; oleic acid, and mixtures thereof. Some preferred oils include those commercially available under the trade names: Capmul MCM, Capmul MCM C-8, Capmul MCM C-10, Capmul PG-8, Miglyol 810, Captex 355, Miglyol 812, Captex 200, Myvacet, Myverol 18-92, Maisine, and Arlacel 186. The amount of oil(s) in the composition may vary over a wide range and the optimum amount for a particular composition will depend on the type and amount of other the other ingredients in the composition as can be determined by the skilled pharmaceutical technician. In general, however, the pharmaceutically acceptable oil is present in an amount of from about 1% to 99% by weight, more preferably in an amount of from about 20% to 70% by weight.

In certain circumstances, e.g. for the purpose of increasing solubility, improving dispersability, pharmaceutically acceptable hydrophilic solvents can optionally be used in



the composition, which include, for example, propylene glycol, polypropylene glycol, polyethylene glycol (e.g., PEG 400), glycerol, ethanol, dimethyl isosorbide, glycofurol, propylene carbonate, dimethyl acetamide, water, or mixtures thereof; preferably, propylene glycol, polyethylene glycol, ethanol, water, or mixtures thereof. A preferred  
5 solvent is a mixture of propylene glycol, ethanol and water. The amount of solvent in the composition may vary over a wide range and the optimum amount for a particular composition will depend on the type and amount of other the other ingredients in the composition as can be easily determined by the skilled worker. In general, however, the solvent(s) are present in an amount of up to about 70% by weight, preferably from about  
10 10% to 30% by weight.

To adjust the viscosity of the formulations or to improve stability, pharmaceutically acceptable polymers can optionally be used in the composition, which include, for example, polyethylene glycols (e.g., PEG 1000, PEG 1500, PEG 3350, PEG 6000 and  
15 PEG 8000), polyvinylpyrrolidones (e.g., Kollidon 12 PF, Kollidon 17 PF, Kollidon 25 PF, Kollidon 30 PF, Kollidon 90 PF etc.), polyvinylalcohols, cellulose derivatives (e.g., hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC)), polyacrylates, polymethacrylates, sugars (e.g., lactose), polyols, and mixtures thereof. When used in the composition, the pharmaceutically acceptable polymer is preferably be present in an  
20 amount up to about 50% by weight, preferably about 1 to 20% by weight.

To facilitate self-emulsification, pharmaceutically acceptable surfactants can optionally be used in the composition, which include, for example, vitamin derivatives such as Vitamin E TPGS (d-alpha tocopheryl polyethylene glycol 1000 succinate), polyoxyl  
25 castor oils (e.g., Cremophor EL), polyoxyl hydrogenated castor oils, polysorbates (e.g., Tween 80), peglicol 6-oleate, polyoxyethylene stearates, polyglycolized glycerides (e.g., Gelucire 44/14) or poloxamers (e.g., Pluronic F68), sodium lauryl sulfate and mixtures thereof. Preferred surfactants include Vitamin E TPGS, polyoxyl 40 hydrogenated castor oil or polyoxyl 35 castor oil, and mixtures thereof.

30

When used in the composition, the surfactant is preferably present in an amount of up to about 70% by weight, preferably from about 20% to 50% by weight. This type of lipid-based system of the present invention further incorporating a surfactant is generally referred to herein as "self-emulsifying drug delivery system" or "SED DS".

5

A particular embodiment of the SED DS composition according to the present invention is directed to a pharmaceutical composition, comprising:

- (a) about 5% to 30% by weight of a compound of formula (I);
- 10 (b) about 0.1% to 7% by weight of a pharmaceutically acceptable amine;
- (c) about 1% to 99% by weight of a pharmaceutically acceptable oil;
- (d) up to about 70% by weight of a pharmaceutically acceptable hydrophilic solvent;
- (e) optionally up to about 50% by weight of a pharmaceutically acceptable polymer;
- 15 (f) up to about 70% by weight of a pharmaceutically acceptable surfactant; and
- (g) optionally about 0.1 to 10% by weight of a pharmaceutically acceptable base.

20

A further particular embodiment of the SED DS composition according to the present invention is directed to a pharmaceutical composition, comprising:

- (a) about 10% to 20% by weight of a compound of formula (I);
- (b) about 0.1% to 5% by weight of a pharmaceutically acceptable amine;
- 25 (c) about 20% to 70% by weight of a pharmaceutically acceptable oil;
- (d) about 10% to 30% by weight of a pharmaceutically acceptable hydrophilic solvent;
- (e) optionally about 1% to 20% by weight of a pharmaceutically acceptable polymer; and
- 30 (f) about 20% to 50% by weight of a pharmaceutically acceptable surfactant; and;

- (g) optionally about 0.1 to 5% by weight of a pharmaceutically acceptable base.

5 A further particular embodiment of the SEDDS composition according to the present invention is directed to a pharmaceutical composition, comprising:

- (a) about 10% to 20% by weight of a compound of formula (I);  
(b) about 0.1% to 5% by weight of tris(hydroxymethyl)aminomethane;  
10 (c) about 20% to 70% by weight of a mono- or diglyceride of caprylic fatty acid or a mono- or diglyceride of capric fatty acid, or mixtures thereof;  
(d) about 10% to 30% by weight of a mixture of propylene glycol, ethanol and optionally water;  
(e) optionally about 1% to 20% by weight of polyethylene glycol or  
15 polyvinylpyrrolidone; and  
(f) about 20% to 50% by weight of d-alpha tocopheryl polyethylene glycol 1000 succinate or polyoxyl 35 castor oil (Cremophor EL); and  
(g) optionally about 0.1 to 5% by weight of sodium hydroxide.

20

The Lipid-Based System composition may be prepared in a conventional manner, for example, by a method comprising: mixing together the liquid components, e.g., the pharmaceutically acceptable oil(s), and any surfactant(s) and solvent(s); dissolving the pharmaceutically acceptable amine(s) and polymer(s) in the resulting mixture; optionally  
25 heating the mixture obtained if necessary to sufficiently melt one or more of the components of the mixture; adding the compound of formula (I) to the resulting mixture and further mixing until all or substantially all of the compound of formula I is solubilized. This method of preparing the composition constitutes another aspect of the present invention. The resulting solution is then optionally formulated into the desired  
30 dosage form, for example, capsules, including hard shell or softgel capsules (e.g., hard or soft gelatin capsules), by known manufacturing technology. Examples of soft gelatin

capsules that can be used include those disclosed in EP 649651 B1 and US Patent 5,985,321.

The composition may also be in the form of a liquid solution or semi-solid for oral, parenteral, rectal or topical administration.

5

### III. Solid Dosage Forms

The present invention also contemplates and includes various solid dosage forms of the composition of the present invention, such as solid dispersions and granulations.


10

#### A. Solid Dispersions

The solid dispersion form of the composition of the present invention comprises:

(a) a compound of formula (I):

15



wherein **B** is H, a C<sub>6</sub> or C<sub>10</sub> aryl, C<sub>7-16</sub> aralkyl; Het or (lower alkyl)-Het, all of which optionally substituted with C<sub>1-6</sub> alkyl; C<sub>1-6</sub> alkoxy; C<sub>1-6</sub> alkanoyl; hydroxy; hydroxyalkyl; halo; haloalkyl; nitro; cyano; cyanoalkyl; amino optionally substituted with C<sub>1-6</sub> alkyl; amido; or (lower alkyl)amide;

or **B** is an acyl derivative of formula R<sub>4</sub>-C(O)-; a carboxyl derivative formula R<sub>4</sub>-O-C(O)-; an amide derivative of formula R<sub>4</sub>-N(R<sub>5</sub>)-C(O)-; a thioamide derivative of formula R<sub>4</sub>-N(R<sub>5</sub>)-C(S)-; or a sulfonyl derivative of formula R<sub>4</sub>-SO<sub>2</sub> wherein

**R<sub>4</sub>** is (i) C<sub>1-10</sub> alkyl optionally substituted with carboxyl, C<sub>1-6</sub> alkanoyl, hydroxy,

- C<sub>1-6</sub> alkoxy, amino optionally mono- or di-substituted with C<sub>1-6</sub> alkyl, amido, or (lower alkyl) amide;
- (ii) C<sub>3-7</sub> cycloalkyl, C<sub>3-7</sub> cycloalkoxy, or C<sub>4-10</sub> alkylcycloalkyl, all optionally substituted with hydroxy, carboxyl, (C<sub>1-6</sub> alkoxy)carbonyl, amino optionally mono- or di-substituted with C<sub>1-6</sub> alkyl, amido, or (lower alkyl) amide;
- (iii) amino optionally mono- or di-substituted with C<sub>1-6</sub> alkyl; amido; or (lower alkyl)amide;
- (iv) C<sub>6</sub> or C<sub>10</sub> aryl or C<sub>7-16</sub> aralkyl, all optionally substituted with C<sub>1-6</sub> alkyl, hydroxy, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with C<sub>1-6</sub> alkyl; or
- (v) Het or (lower alkyl)-Het, both optionally substituted with C<sub>1-6</sub> alkyl, hydroxy, amido, (lower alkyl) amide, or amino optionally mono- or di-substituted with C<sub>1-6</sub> alkyl;
- R<sub>5</sub> is H or C<sub>1-6</sub> alkyl;
- with the proviso that when B is a carboxyl derivative, an amide derivative or a thioamide derivative, R<sub>4</sub> is not a cycloalkoxy;
- Y is H or C<sub>1-6</sub> alkyl;
- R<sup>3</sup> is C<sub>1-8</sub> alkyl, C<sub>3-7</sub> cycloalkyl, or C<sub>4-10</sub> alkylcycloalkyl, all optionally substituted with hydroxy, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> thioalkyl, amido, (lower alkyl)amido, C<sub>6</sub> or C<sub>10</sub> aryl, or C<sub>7-16</sub> aralkyl;
- R<sup>2</sup> is CH<sub>2</sub>-R<sub>20</sub>, NH-R<sub>20</sub>, O-R<sub>20</sub> or S-R<sub>20</sub>, wherein R<sub>20</sub> is quinolyl or (lower alkyl)quinolyl, both optionally mono-, di- or tri-substituted with R<sub>21</sub>, wherein each R<sub>21</sub> is independently C<sub>1-6</sub> alkyl; C<sub>1-6</sub> alkoxy; lower thioalkyl; sulfonyl; NO<sub>2</sub>; OH; SH; halo; haloalkyl; amino optionally mono- or di-substituted with C<sub>1-6</sub> alkyl, C<sub>6</sub> or C<sub>10</sub> aryl, C<sub>7-14</sub> aralkyl, Het or (lower alkyl)-Het; amido optionally mono-substituted with C<sub>1-6</sub> alkyl, C<sub>6</sub> or C<sub>10</sub> aryl, C<sub>7-14</sub> aralkyl, Het or (lower alkyl)-Het; carboxyl; carboxy(lower alkyl); C<sub>6</sub> or C<sub>10</sub> aryl, C<sub>7-14</sub> aralkyl or Het, said aryl, aralkyl or Het being optionally substituted with R<sub>22</sub>;
- wherein R<sub>22</sub> is C<sub>1-6</sub> alkyl; C<sub>3-7</sub> cycloalkyl; C<sub>1-6</sub> alkoxy; amino optionally mono- or di-substituted with C<sub>1-6</sub> alkyl or C<sub>3-7</sub>cycloalkyl; sulfonyl; (lower alkyl)sulfonyl; NO<sub>2</sub>; OH; SH; halo; haloalkyl; carboxyl; amide; (lower

alkyl)amide; or Het optionally substituted with C<sub>1-6</sub> alkyl;

R<sup>1</sup> is H; C<sub>1-6</sub> alkyl, C<sub>3-7</sub> cycloalkyl, C<sub>2-6</sub> alkenyl, or C<sub>2-6</sub> alkynyl, all optionally substituted with halogen;

or a tautomer thereof;

5

(b) about 0.1 to 10% by weight of a pharmaceutically acceptable amine or a mixture of pharmaceutically acceptable amines;

(c) one or more pharmaceutically acceptable carriers; and

10

(d) optionally one or more pharmaceutically acceptable surfactants.

The pharmaceutical composition may optionally further contain one or more pharmaceutically acceptable bases.

15

The amount of the active ingredient (formula (I) compound) that may be present in the solid dispersion composition may vary widely or be adjusted widely depending on the intended route of administration, the potency of the particular active ingredient being used, the severity of the hepatitis C viral infection and the required concentration. In a particular embodiment, the compound of formula (I) is present in the solid dispersion in an amount of from about 1% to 50% by weight, preferably from about 5% to 30% by weight, more preferably from about 10% to 20% by weight.

20

Pharmaceutically acceptable amines useful in the composition include, for example, C<sub>1-6</sub> alkylamine, di-(C<sub>1-6</sub> alkyl)-amine or tri-(C<sub>1-6</sub> alkyl)-amine, wherein one or more alkyl groups thereof may be optionally substituted by one or more hydroxy groups, or C<sub>1-6</sub> alkylenediamine, a basic amino acid or choline hydroxide, or mixtures thereof. Specific amines include ethanolamine, diethanolamine, triethanolamine, tris(hydroxymethyl)aminomethane, ethylenediamine or dimethylaminoethanol, or mixtures thereof. A preferred amine is tris(hydroxymethyl)aminomethane (also called "Tris"; and "tromethamine"). The amine is present in an amount of about 0.1 to 10% by

30

weight, more preferably in an amount of from about 0.1% to 7% by weight; even more preferably from about 0.1% to 5% by weight .

Pharmaceutically acceptable carriers that can be used in the composition include any  
5 substance that can effectively retain the active ingredient of formula (I) in dispersed state  
in a final solid dosage form. Suitable pharmaceutically acceptable carriers include, for  
example, pharmaceutically acceptable polymers and pharmaceutically acceptable ureas.  
Preferred carriers include polyethylene glycols (e.g., PEG 1000, PEG 1500, PEG 3350,  
PEG 4600, PEG 6000 and PEG 8000), polyvinylpyrrolidones (e.g., Kollidon 12 PF,  
10 Kollidon 17 PF, Kollidon 25 PF, Kollidon 30 PF, Kollidon 90 PF etc.),  
polyvinylalcohols, cellulose derivatives (e.g., hydroxypropylmethylcellulose (HPMC),  
hydroxypropylcellulose (HPC)), polyacrylates, polymethacrylates, polyglycolized  
glycerides, ureas, sugars (e.g., lactose), polyols, and mixtures thereof. The best carrier  
to be used for a particular composition will depend on a variety of factors including the  
15 other ingredients in the composition and the specific method to be employed in the  
preparation of the composition, e.g., co-melting or co-precipitation, as discussed below.  
For example, when preparing the composition using the co-melt process it is desirable to  
use a carrier that can be melted under suitable laboratory conditions, for example, at less  
than about 100 °C, preferably less than about 80 °C. When preparing the composition  
20 using the co-precipitation process it is desirable to use a carrier that can be dissolved in a  
suitable hydrophilic solvent along with the other ingredients such that co-precipitation  
can take place.

The amount of pharmaceutically acceptable carrier may vary over a wide range and the  
25 optimum amount for a particular composition will again depend on the other ingredients  
in the composition and the method of preparation to be employed, and can be easily  
determined by the skilled pharmaceutical technician. In general, however, the  
pharmaceutically acceptable carrier may be present in the solid dispersion composition in  
an amount up from about 1 to 99% by weight, preferably about 60% to 80% by weight.

30

In order to achieve improved dispersion and dissolution performance, pharmaceutically

acceptable surfactants can optionally be used in the composition, which include, for example, vitamin derivatives such as Vitamin E TPGS (d-alpha tocopheryl polyethylene glycol 1000 succinate), polyoxyl castor oils (e.g., Cremophor EL), polyoxyl hydrogenated castor oils, polysorbates (e.g., Tween 80), peglicol 6-oleate, 5 polyoxyethylene stearates, polyglycolized glycerides such as lauroyl macroglycerides (Gelucire 44/14), poloxamers such as polyoxypropylene-polyoxyethylene block copolymer (Pluronic F68), sodium lauryl sulfate (SLS) and mixtures thereof. Preferred surfactants include Vitamin E TPGS, Pluronic F68, or sodium lauryl sulfate, and mixtures thereof. When used in the composition, the surfactant is preferably present in an amount 10 of up to about 50% by weight, preferably from about 1% to 20% by weight.

Pharmaceutically acceptable bases useful in the composition include, for example, potassium hydroxide, sodium hydroxide, sodium hydrogen carbonate, aluminum hydroxide, calcium carbonate, magnesium hydroxide, magnesium aluminum silicate, 15 synthetic aluminum silicate, synthetic hydrotalcite, magnesium aluminum hydroxide. Also suitable are bases which are salts of a pharmaceutically acceptable acid, such as acetic acid, acrylic acid, adipic acid, alginic acid, alkanesulfonic acid, amino acids, ascorbic acid, benzoic acid, boric acid, butyric acid, carbonic acid, citric acid, fatty acids, formic acid, fumaric acid, gluconic acid, hydroquinosulfonic acid, isoascorbic acid, lactic 20 acid, maleic acid, oxalic acid, para-bromophenylsulfonic acid, propionic acid, p-toluenesulfonic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, thioglycolic acid, toluenesulfonic acid, uric acid, and the like. Salts of polyprotic acids, such as sodium phosphate, disodium hydrogen phosphate, and sodium dihydrogen phosphate can also be used. When the base is a salt, the cation can be any convenient and 25 pharmaceutically acceptable cation, such as ammonium, alkali metals, alkaline earth metals, and the like. Preferred cations include sodium, potassium, lithium, magnesium, calcium and ammonium. Some preferred bases include sodium hydroxide, potassium hydroxide, sodium hydrogen carbonate, aluminum hydroxide, magnesium hydroxide and magnesium aluminum hydroxide. When used in the composition, the pharmaceutically 30 acceptable base is preferably present in the composition in an amount of from about 0.1



to 10% by weight, for example about 0.1 to 5% by weight, for example about 0.1 to 3% by weight.

A particular embodiment of the solid dispersion composition is directed to a  
5 pharmaceutical composition comprising:

- (a) about 5% to 30% by weight of a compound of formula (I);
- (b) about 0.1% to 7% by weight of a pharmaceutically acceptable amine;
- (c) about 1% to 99% by weight of a pharmaceutically acceptable carrier; and
- (d) up to about 50% by weight of a pharmaceutically acceptable surfactant.

10

A further particular embodiment of the solid dispersion composition is directed to a pharmaceutical composition comprising:

- (a) about 10% to 20% by weight of a compound of formula (I);
- (b) about 0.1% to 5% by weight of a pharmaceutically acceptable amine;
- 15 (c) about 60% to 80% by weight of a pharmaceutically acceptable carrier; and
- (d) about 1% to 20% by weight of a pharmaceutically acceptable surfactant.

A further particular embodiment of the solid dispersion composition is directed to a pharmaceutical composition comprising:

- 20 (a) about 10% to 20% by weight of a compound of formula (I);
- (b) about 0.1% to 5% by weight of tris(hydroxymethyl)aminomethane;
- (c) about 60% to 80% by weight of polyethylene glycol,  
polyvinylpyrrolidone, lactose or a mixture thereof; and
- (d) about 1% to 20% by weight of d-alpha tocopheryl polyethylene glycol  
25 1000 succinate, polyoxypropylene-polyoxyethylene block copolymer, or  
sodium lauryl sulfate.

The solid dispersion composition may be prepared by two alternative methods: the co-melt method or the co-precipitation method, each of which constitutes another aspect of  
30 the present invention.

The co-melt method comprises: (a) mixing the pharmaceutically acceptable carrier(s) and the optional surfactant(s) and heating the resulting mixture to sufficiently melt the carrier(s) and surfactant(s); (b) adding the pharmaceutically acceptable amine(s) and the compound of formula (I) to the mixture obtained in step (a) and mixing until all or  
5 substantially all of the compound of formula (I) is solubilized. The resulting dispersion is then allowed to cool and form a solid or semi-solid dispersion. The resulting dispersion is then optionally formulated into the desired dosage form such as, for example, capsules, including hard shell or softgel capsules, by known manufacturing technology. Examples of soft gelatin capsules that can be used include those disclosed in EP 649651 B1 and US  
10 Patent 5,985,321.

The co-precipitation method comprises: (a) dissolving the pharmaceutically acceptable amine(s), the pharmaceutically acceptable carrier(s) and optionally the pharmaceutically acceptable surfactant(s) in a suitable hydrophilic solvent; (b) adding the compound of  
15 formula (I) to the solution obtained in step (a) and mixing to dissolve the compound of formula (I); and (c) evaporating the hydrophilic solvent to cause co-precipitation of the compound of formula (I), the amine(s), the carrier(s) and the optional surfactant(s). Preferred hydrophilic solvents for use in this process include ethanol, methanol and chloroform. The resulting co-precipitated solid or semi-solid dispersion, generally a  
20 powder, is then optionally formulated into the desired dosage form such as, for example, tablets or capsules, including hard shell or softgel capsules, by known manufacturing technology. Examples of soft gelatin capsules that can be used include those disclosed in EP 649651 B1 and US Patent 5,985,321.

25

#### B. Granulations

The pharmaceutical compositions of the present invention may also be in the form of granulations which are prepared using conventional granulation techniques. Such granulations may generally comprise the same ingredients in the same amounts as is set  
30 forth above with respect to the solid dispersion compositions according to the present invention. The resulting granulation is then optionally formulated into the desired dosage

form such as, for example, compressed into tablets or filled into capsules, including hard shell capsules, by known manufacturing technology.

The granulations may be prepared by two alternative methods: dry granulation method  
5 and wet granulation method, each of which constitutes another aspect of the present invention.

The dry granulation method comprises: (a) triturating and mixing the compound of formula (I), the pharmaceutically acceptable amine(s), the pharmaceutically acceptable  
10 carrier(s) and optionally the pharmaceutically acceptable surfactant(s) to form a blend; and (b) optionally adding to the blend a lubricant, e.g. <1% by weight of magnesium stearate. The resulting blended powder may be compressed into tablets.

The wet granulation method comprises: (a) mixing the compound of formula (I), the  
15 pharmaceutically acceptable amine(s), the pharmaceutically acceptable carrier(s) and optionally the pharmaceutically acceptable surfactant(s) while adding water or another hydrophilic solvent(s) to the mixture to obtain a paste; (b) drying the paste of step (a) to a sufficient level of dryness; and (c) passing the dried paste through a screen. The resulting granules may be filled into capsules or compressed into tablets.

20

#### IV. Optional Additional Ingredients

If desired, the compositions according to the present invention may further include conventional pharmaceutical additives as is necessary or desirable to obtain a suitable  
25 formulation, such as antioxidants, lubricants, disintegrants, preservatives, buffers, stabilizers, thickening agents, coloring agents, sweetening agents, flavoring agents, fragrances, etc. Additional additives that may be useful in the compositions of the invention are disclosed in Llinas-Brunet et al., U.S. Patent No. 6,323,180 B1.

30 In one preferred embodiment, the compositions according to the present invention further contain one or more antioxidants. Preferred antioxidants include, for example, ascorbic

acid, sulfatide salts, citric acid, propyl gallate, dl- $\alpha$ -tocopherol, ascorbyl palmitate, BHT or BHA. If present, the antioxidant is generally present in an amount of from about 0.01% to 1% by weight.

5

V. Compounds of Formula (I)

- 10 More specific embodiments for the compounds of formula (I) in the compositions are as set forth below.

One embodiment is directed to a compound of formula (I) wherein:

**B** is a carboxyl derivative of formula  $R_4-O-C(O)-$ , wherein  $R_4$  is

- 15 (i)  $C_{1-10}$  alkyl optionally substituted with carboxyl,  $C_{1-6}$  alkanoyl, hydroxy,  $C_{1-6}$  alkoxy, amino optionally mono- or di-substituted with  $C_{1-6}$  alkyl, amido or (lower alkyl)amide;
- (ii)  $C_{3-7}$  cycloalkyl,  $C_{4-10}$  alkylcycloalkyl, all optionally substituted with carboxyl, ( $C_{1-6}$  alkoxy)carbonyl, amino optionally mono- or di-substituted with  $C_{1-6}$  alkyl,
- 20 amido or (lower alkyl)amide;
- (iv)  $C_6$  or  $C_{10}$  aryl or  $C_{7-16}$  aralkyl optionally substituted with  $C_{1-6}$  alkyl, hydroxy, amido, (lower alkyl)amido, or amino optionally mono- or di-substituted with  $C_{1-6}$  alkyl; or
- (v) Het or (lower alkyl)-Het, both optionally substituted with  $C_{1-6}$  alkyl, hydroxy,
- 25 amino optionally mono- or di-substituted with  $C_{1-6}$  alkyl, amido or (lower alkyl)amido.

Another embodiment is directed to a compound of formula (I) wherein:

**B** is a carboxyl derivative of formula  $R_4-O-C(O)-$ , wherein  $R_4$  is

- 30 (i)  $C_{1-10}$  alkyl optionally substituted with carboxyl,  $C_{1-6}$  alkanoyl, hydroxy,  $C_{1-6}$  alkoxy or amido, (lower alkyl)amide, amino optionally mono- or di-substituted

with C<sub>1-6</sub> alkyl; or

(ii) C<sub>3-7</sub> cycloalkyl, C<sub>4-10</sub> alkylcycloalkyl, all optionally substituted with carboxyl, (C<sub>1-6</sub> alkoxy)carbonyl, amido, (lower alkyl)amide, amino optionally mono- or di-substituted with C<sub>1-6</sub> alkyl.

- 5 Another embodiment is directed to a compound of formula (I) wherein: Y is H or methyl.

Another embodiment is directed to a compound of formula (I) wherein:

- 10 R<sup>3</sup> is C<sub>1-8</sub> alkyl, C<sub>3-7</sub> cycloalkyl, or C<sub>4-10</sub> alkylcycloalkyl, all optionally substituted with hydroxy, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> thioalkyl, acetamido, C<sub>6</sub> or C<sub>10</sub> aryl, or C<sub>7-16</sub> aralkyl.

Another embodiment is directed to a compound of formula (I) wherein: R<sup>3</sup> is C<sub>1-8</sub> alkyl, for example, tert-butyl.

- 15 Another embodiment is directed to a compound of formula (I) wherein:

R<sub>21</sub> is C<sub>1-6</sub> alkyl; C<sub>1-6</sub> alkoxy; lower thioalkyl; amino or amido optionally mono- or di-substituted with C<sub>1-6</sub> alkyl, C<sub>6</sub> or C<sub>10</sub> aryl, C<sub>7-16</sub> aralkyl, Het or (lower alkyl)-Het; NO<sub>2</sub>; OH; halo; trifluoromethyl; carboxyl; C<sub>6</sub> or C<sub>10</sub> aryl, C<sub>7-16</sub> aralkyl, or Het, said aryl, aralkyl or Het being optionally substituted with R<sub>22</sub>, wherein

- 20 R<sub>22</sub> is C<sub>1-6</sub> alkyl; C<sub>3-7</sub> cycloalkyl; C<sub>1-6</sub> alkoxy; amino optionally mono- or di-substituted with C<sub>1-6</sub> alkyl or C<sub>3-7</sub> cycloalkyl; amide; (lower alkyl)amide; sulfonylalkyl; NO<sub>2</sub>; OH; halo; trifluoromethyl; carboxyl or Het.


Another embodiment is directed to a compound of formula (I) wherein:

- 25 R<sub>21</sub> is C<sub>1-6</sub> alkyl; C<sub>1-6</sub> alkoxy; amino; di(lower alkyl)amino; (lower alkyl)amide; C<sub>6</sub> or C<sub>10</sub> aryl, or Het, said aryl or Het being optionally substituted with R<sub>22</sub>, wherein R<sub>22</sub> is C<sub>1-6</sub> alkyl; C<sub>3-7</sub> cycloalkyl; C<sub>1-6</sub> alkoxy; amino optionally mono- or di-substituted with C<sub>1-6</sub> alkyl or C<sub>3-7</sub> cycloalkyl; amido; (lower alkyl)amide; halo; trifluoromethyl or Het.


- 30 Another embodiment is directed to a compound of formula (I) as described above wherein R<sub>22</sub> is amino optionally mono- or di-substituted with C<sub>1-6</sub> alkyl or C<sub>3-7</sub> cycloalkyl;

amido; or C<sub>1-6</sub> alkyl-C(O)-NH-.

Another embodiment is directed to a compound of formula (I) wherein R<sup>2</sup> is selected from the group consisting of:



Another embodiment is directed to a compound of formula (I) wherein R<sup>2</sup> is :





10 wherein R<sub>21A</sub> is C<sub>1-6</sub> alkyl; C<sub>1-6</sub> alkoxy; lower thioalkyl; halo; amino optionally mono-substituted with C<sub>1-6</sub> alkyl; or C<sub>6</sub>, C<sub>10</sub> aryl, C<sub>7-16</sub> aralkyl, or Het, said aryl, aralkyl or Het optionally substituted with R<sub>22</sub> wherein R<sub>22</sub> is C<sub>1-6</sub> alkyl; C<sub>1-6</sub> alkoxy; amido; amino optionally mono- or di-substituted with C<sub>1-6</sub>alkyl or C<sub>3-7</sub> cycloalkyl; (lower alkyl)amide or Het; and

15 R<sub>21B</sub> is C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, amino, di(lower alkyl)amino, (lower alkyl)amide, NO<sub>2</sub>, OH, halo, trifluoromethyl, or carboxyl.


Another embodiment is directed to a compound of formula (I) as described above and wherein R<sub>21A</sub> is C<sub>6</sub>, C<sub>10</sub> aryl or Het, all optionally substituted with R<sub>22</sub> as defined above.

20 Another embodiment is directed to a compound of formula (I) as described above and wherein R<sub>21A</sub> is selected from the group consisting of:






Another embodiment is directed to a compound of formula (I) wherein  $R^2$  is:



10 wherein  $R_{22A}$  is  $C_{1-6}$  alkyl;  $C_{1-6}$  alkoxy; or halo; and  $R_{21B}$  is  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy, amino, di(lower alkyl)amino, (lower alkyl)amide,  $NO_2$ , OH, halo, trifluoromethyl, or carboxyl.

Another embodiment is directed to a compound of formula (I) wherein  $R^2$  is:



wherein **R<sub>22B</sub>** is C<sub>1-6</sub> alkyl; amino optionally mono- or di-substituted with C<sub>1-6</sub>alkyl or C<sub>3-7</sub> cycloalkyl; (lower alkyl)amide; or amido; and **R<sub>21B</sub>** is C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, amino, di(lower alkyl)amino, (lower alkyl)amide, NO<sub>2</sub>, OH, halo, trifluoromethyl, or carboxyl.

5


Another embodiment is directed to a compound of formula (I) as described above and wherein **R<sub>21B</sub>** is C<sub>1-6</sub> alkoxy or di(lower alkyl)amino; and **R<sub>22B</sub>** is amino mono-substituted with C<sub>3-7</sub> cycloalkyl; or is C<sub>1-6</sub> alkyl-C(O)-NH-.

- 10 Another embodiment is directed to a compound of formula (I) as described above and wherein wherein **R<sub>21B</sub>** is methoxy or dimethylamino.

Another embodiment is directed to a compound of formula (I) as described above and wherein **R<sup>1</sup>** is H, C<sub>1-3</sub> alkyl, C<sub>3-5</sub> cycloalkyl, or C<sub>2-4</sub> alkenyl, all optionally substituted with

15 halo.

Another embodiment is directed to a compound of formula (I) as described above and




wherein **P1** is

and **R<sup>1</sup>** is ethyl, vinyl, cyclopropyl, 1 or 2-bromoethyl or 1 or 2-bromovinyl, and more

20 specifically wherein **R<sup>1</sup>** is vinyl.


When **R<sup>1</sup>** is not H, then in one embodiment **P1** contains a cyclopropyl system of formula:






wherein C<sub>1</sub> and C<sub>2</sub> each represent an asymmetric carbon atom at positions 1 and 2 of the cyclopropyl ring. Notwithstanding other possible asymmetric centers at other segments of the compounds of formula I, the presence of these two asymmetric centers means that the compounds of formula I can exist as racemic mixtures of diastereoisomers. The racemic mixtures can be prepared and thereafter separated into individual optical isomers, or these optical isomers can be prepared by chiral synthesis, using conventional methods.

Hence, the compounds of formula I can exist as a racemic mixture of diastereoisomers at carbon 1 but wherein R<sup>1</sup> at carbon 2 is orientated *syn* to the carbonyl at position 1, represented by the radical:




or the compound of formula I can exist as a racemic mixture of diastereoisomers wherein R<sup>1</sup> at position 2 is orientated *anti* to the carbonyl at position 1, represented by the radical:




In turn, the racemic mixtures can be separated into individual optical isomers.

A particular embodiment is one wherein  $R^1$  is not H and carbon 1 has the *R* configuration.




5

Another particular embodiment is one wherein  $R^1$  at carbon 2 is orientated *syn* to the carbonyl at position 1, represented by the radical:



Another particular embodiment is one wherein said  $R^1$  substituent and the carbonyl are in a *syn* orientation in the following absolute configuration:



Another embodiment is directed to a compound of formula (I) as described above and wherein  $R^1$  is ethyl.

15

Another embodiment is directed to a compound of formula (I) as described above and wherein  $R^1$  is vinyl.

Another embodiment is directed to a compound of formula (I) wherein:


**B** is a carboxyl derivative of formula  $R_4-O-C(O)-$ , wherein  $R_4$  is

$C_{3-7}$  cycloalkyl, or  $C_{4-10}$  alkylcycloalkyl, all optionally substituted with carboxyl,  $(C_{1-6}$  alkoxy)carbonyl, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with  $C_{1-6}$  alkyl;


5 **Y** is H or methyl;

$R^3$  is  $C_{1-8}$  alkyl;

$R^2$  is:



wherein  $R_{22B}$  is  $C_{1-6}$  alkyl; amino optionally mono- or di-substituted with  $C_{1-6}$ alkyl or  $C_{3-7}$  cycloalkyl; (lower alkyl)amide; or amido; and  $R_{21B}$  is  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy, amino, di(lower alkyl)amino, (lower alkyl)amide,  $NO_2$ , OH, halo, trifluoromethyl, or carboxyl; and



**P1** is


and  $R^1$  is ethyl, vinyl, cyclopropyl, 1 or 2-bromoethyl or 1 or 2-bromovinyl;

15

Numerous specific compounds that are representative of the compounds of the present invention may be found in Llinas-Brunet et al., U.S. Patent No. 6,323,180 B1, (referred to hereinafter as "Llinas-Brunet et al."), which is herein incorporated by reference.

Some specific compounds are also shown in the Table below:

20



wherein  $R_{21}$  and  $R_{22}$  are as defined below:


5

Cpd #	$R_{21}$	$R_{22}$
1101	MeO-	
1102	MeO-	
1103	MeO-	
1104	MeO-	
and 1105	(Me) <sub>2</sub> N-	

The compounds of formula I may be synthesized by the procedures fully set forth in Llinas-Brunet et al. For example, the compounds of formula I may be synthesized

according to a general process as illustrated in scheme I (wherein CPG is a carboxyl protecting group and APG is an amino protecting group):

SCHEME I



- 5 Briefly, the P1, P2, and P3 can be linked by well known peptide coupling techniques. The P1, P2, and P3 groups may be linked together in any order as long as the final compound corresponds to peptides of Formula I. For example, P3 can be linked to P2-P1 ; or P1 linked to P3-P2. Llinas-Brunet et al. provides numerous examples of preparing various compounds of the formula (I) using this synthetic procedure.

10

#### Methods of Therapeutic Use

- The compounds of formula I are effective as HCV protease inhibitors, and these compounds and pharmaceutical compositions comprising these compounds are therefore  
15 useful in inhibiting the replication of HCV and in the treatment of HCV infections.

- As discussed above, the pharmaceutical compositions of the present invention may be formulated into a variety of dosage forms depending upon the particular composition contemplated. Likewise, a variety of modes of administration are possible depending  
20 upon the particular composition and dosage form, although oral administration by tablet, capsule or suspension are the preferred modes of administration.

Dosage levels of the compounds of formula (I) and various treatment regimens in the monotherapy for the prevention and treatment of HCV infection that would be useful are

as set forth in Llinas-Brunet et al. As the skilled artisan will appreciate, however, lower dosages may be possible with the compositions of the present invention depending on the level of improvement in bioavailability. Combination therapy is also possible with one or more additional therapeutic or prophylactic agents as fully described by Llinas-Brunet et al. The additional agent(s) may be combined with the compounds of this invention to create a single dosage form or, alternatively, these additional agent(s) may be separately administered to a mammal as part of a multiple dosage form.

In order that this invention be more fully understood, the following examples are set forth. These examples are for the purpose of illustrating embodiments of this invention, and are not to be construed as limiting the scope of the invention in any way.

### Examples

#### Formulation #1 (Co-Solvent System)

Ingredient	Weight (mg/g)	%(w/w)
Compound of formula (I)	40	4
Tromethamine	32	3.2
Water	448	44.8
Ethanol	213	21.3
Propylene glycol	267	26.7

#### Formulation #2 (Co-Solvent System)

Ingredient	Weight (mg/g)	%(w/w)
Compound of formula (I)	100	10
Tromethamine	30	3
Water	420	42
Ethanol	200	20

Propylene glycol	250	25
------------------	-----	----

#### Preparation of Formulations 1 and 2:

- 5 First, Tromethamine is dissolved in a mixture of water, ethanol and propylene glycol in a tightly capped container, and then a Compound of formula (I) is added to the solution and stirring is continued until all the drug becomes soluble.

#### Formulation #3 (SEDDS)

10

Ingredient	Weight (mg/g)	%(w/w)
Compound of formula (I)	40	4
Tromethamine	8	0.8
Ethanol	94.7	9.47
Propylene glycol	111.5	11.15
Water	16	1.6
Propyl gallate	2	0.2
Capmul MCM	334.4	33.44
Cremophor EL	393.4	39.34

#### Formulation #4 (SEDDS)

Ingredient	Weight (mg/g)	%(w/w)
Compound of formula (I)	125	12.5
Tromethamine	20	2
Ethanol	50	5
Propylene glycol	50	5
Water	20	2
Propyl gallate	2	0.2
PEG3350	75	7.5
Capmul MCM	329	32.9
V <sub>E</sub> TPGS	329	32.9

#### 15 Formulation #5 (Lipid-Based System)

Ingredient	Weight (mg/g)	%(w/w)
Compound # 1104	100	10
Tromethamine	4	0.4
Ethanol	100	10
Alpha-Tocopherol	2	0.2

Kollidon 12PF	50	5
Capmul MCM	744	74.4

Formulation #6 (SEDDS)

Ingredient	Weight (mg/g)	%(w/w)
Compound # 1104	100	10
Tromethamine	4	0.4
Ethanol	100	10
Propylene glycol	50	5
Alpha-Tocopherol	2	0.2
Kollidon 12PF	50	5
Capmul MCM	347	34.7
V <sub>E</sub> TPGS	347	34.7

Formulation #7 (SEDDS)

Ingredient	Weight (mg/g)	%(w/w)
Compound of formula (I)	100	10
Tromethamine	10	1
Ethanol	100	10
Propylene glycol	50	5
Water	20	2
Alpha-Tocopherol	4	0.4
Capmul MCM	220	22
V <sub>E</sub> TPGS	496	49.6

5

Formulation #8 (SEDDS)

Ingredient	Weight (mg/g)	%(w/w)
Compound of formula (I)	100	10
Tromethamine	10	1
Sodium hydroxide	3	0.3
Ethanol	100	10
Propylene glycol	50	5
Water	30	3
Alpha-Tocopherol	4	0.4
Captex 355	220	22
V <sub>E</sub> TPGS	483	48.3

Preparation of Formulations 3, 4, 5, 6, 7 and 8:



First, the liquid components such as Capmul MCM or Captex 355, Cremophor EL, propylene glycol, water and ethanol are mixed together in a tightly capped container, and then Tromethamine and antioxidant are dissolved in the mixture. Finally, a Compound of formula (I) is added to the container and stirring is continued until the drug is completely solubilized. When V<sub>E</sub> TPGS is in the formulation, the mixture is heated at 40°C in a water bath to melt it before the drug is added. These formulations can be filled into hard shell or soft gelatin capsules.

Formulation #9 (Solid Dispersion - Co-Melt)

Ingredient	Weight (mg/g)	%(w/w)
Compound # 1104	125	12.5
Tromethamine	20	2
PEG1000	755	75.5
V <sub>E</sub> TPGS	100	10

Formulation #10 (Solid Dispersion - Co-Melt)

Ingredient	Weight (mg/g)	%(w/w)
Compound of formula (I)	100	10
Tromethamine	30	3
PEG1450	770	77
V <sub>E</sub> TPGS	100	10

Preparation of Formulations 9 and 10:

PEG and V<sub>E</sub> TPGS are placed in a tightly capped container and melted at 60°C in a water bath. Then, Tromethamine and Compound of formula (I) are added to the container and stirring is continued at the same temperature until the drug is completely solubilized. These formulations can be filled into hard shell or soft gelatin capsules.

Formulation #11 (Solid Dispersion - Co-Precipitate - Comparison Formulation)

Ingredient	Weight (mg/g)	%(w/w)
Compound of	200	20

formula (I)		
Kollidon 25	800	80

**Formulation #12 (Solid Dispersion - Co-Precipitate - Invention Formulation)**

5

Ingredient	Weight (mg/g)	% (w/w)
Compound of formula (I)	300	30
Kollidon 25	670	67
Tween 80	20	2
Tromethamine	10	1

**Preparation of Formulations 11 and 12:**

10 Kollidon 25 and other excipients (e.g., Tween 80 and tromethamine) are dissolved in a sufficient amount of ethanol in a glass container. Then Compound of formula (I) is added to the container and stirred until the compound is completely dissolved. The ethanol is removed by placing the container in a vacuum oven at RT. After the ethanol is completely evaporated, the solid material (co-precipitate) is taken out from the glass container and passed through a 1-mm screen. The powder can be filled into  
 15 hard shell capsules or further compressed into tablets. The solvent used to dissolve the drug and the excipients can be ethanol, methanol, or chloroform.

**Formulation #13 (Dry Granulation)**

Ingredient	Weight (mg/g)	% (w/w)
Compound of formula (I)	225	22.5
Lactose	675	67.5
Tromethamine	67.5	6.75
SLS	22.5	2.25
Mg Stearate	10	1.0

20

**Formulation #14 (Dry Granulation)**

Ingredient	Weight (mg/g)	% (w/w)
Compound of formula (I)	225	22.5
PEG 4600	675	67.5
Tromethamine	67.5	6.75
SLS	22.5	2.25
Mg Stearate	10	1.0

5

**Preparation of Formulations #13 and #14:**

In a glass mortar, the formulation ingredients are triturated for about 2 minutes with a glass pestle. The mixture is transferred into a glass bottle and blended with a torbola blender for 6 minutes. The magnesium stearate is added to the powder and blending is continued for another 4 minutes. The powder can be compressed into tablets @ 6.6KN using a 11 mm die set.

10

**Formulation #15 (Wet Granulation)**

Ingredient	Weight (mg/g)	% (w/w)
Compound of formula (I)	238	23.8
Lactose	714	71.4
PVP (5%)	48	4.8

15

**Formulation #16 (Wet Granulation)**

Ingredient	Weight (mg/g)	% (w/w)
Compound of formula (I)	230	23
Lactose	688	68.8
Tromethamine	34	3.4
PVP (5%)	48	4.8

**Formulation #17 (Wet Granulation)**

Ingredient	Weight (mg/g)	% (w/w)
Compound of formula (I)	216	21.6
PEG 4600	649	64.9
Tromethamine	65	6.5
SLS	22	2.2
PVP (5%)	48	4.8

**5 Preparation of Formulations # 15, 16 and 17:**

In a glass mortar, the formulation ingredients are triturated for about 2 minutes with the glass pestle. Hot water (80°C) is added dropwise to the mixture while stirring with the pestle. Water addition is continued until a paste is obtained. The paste is  
10 dried in a petridish in an oven at 45°C. After 2 hours drying, the paste is triturated and passed through a mesh #18. The powder is dried until the weight is constant and equal to the initial weight. The powder can be filled into hard shell capsules or compressed into tablets.

**15 In-Vitro Dispersion and Dissolution Studies**

**(1) Dispersion test**

To assess the dispersability, each prepared formulation may be diluted with pH 2.0  
20 (0.05M HCl/KCl) and pH 6.8 buffer (0.05M KH<sub>2</sub>PO<sub>4</sub>/K<sub>2</sub>HPO<sub>4</sub>), the dispersion is observed as clear solution, colloidal dispersion (emulsion or microemulsion) or suspension with drug precipitation. Formulations with no drug precipitation in the buffers and faster dispersion rate are preferred.


(2) Dissolution test

- 5      USP XXIII apparatus (paddle method, 50 rpm) may be used to obtain the release of drug from selected formulations into 900 ml pH 2.0 buffer (0.05M HCl/KCl) dissolution medium at 37 °C. Samples of 10 ml are withdrawn at various time intervals and drug concentration is determined by HPLC. Formulations with faster and higher drug release are preferred.

## CLAIMS

We Claim:

1. A pharmaceutical composition comprising:
- (a) a compound having the following formula (I):



- wherein **B** is H, a C<sub>6</sub> or C<sub>10</sub> aryl, C<sub>7-16</sub> aralkyl; Het or (lower alkyl)-Het, all of which optionally substituted with C<sub>1-6</sub> alkyl; C<sub>1-6</sub> alkoxy; C<sub>1-6</sub> alkanoyl; hydroxy; hydroxyalkyl; halo; haloalkyl; nitro; cyano; cyanoalkyl; amino optionally substituted with C<sub>1-6</sub> alkyl; amido; or (lower alkyl)amide;
- or **B** is an acyl derivative of formula R<sub>4</sub>-C(O)-; a carboxyl derivative formula R<sub>4</sub>-O-C(O)-; an amide derivative of formula R<sub>4</sub>-N(R<sub>5</sub>)-C(O)-; a thioamide derivative of formula R<sub>4</sub>-N(R<sub>5</sub>)-C(S)-; or a sulfonyl derivative of formula R<sub>4</sub>-SO<sub>2</sub> wherein
- R<sub>4</sub> is (i) C<sub>1-10</sub> alkyl optionally substituted with carboxyl, C<sub>1-6</sub> alkanoyl, hydroxy, C<sub>1-6</sub> alkoxy, amino optionally mono- or di-substituted with C<sub>1-6</sub> alkyl, amido, or (lower alkyl) amide;
- (ii) C<sub>3-7</sub> cycloalkyl, C<sub>3-7</sub> cycloalkoxy, or C<sub>4-10</sub> alkylcycloalkyl, all optionally substituted with hydroxy, carboxyl, (C<sub>1-6</sub> alkoxy)carbonyl, amino optionally mono- or di-substituted with C<sub>1-6</sub> alkyl, amido, or (lower alkyl) amide;
- (iii) amino optionally mono- or di-substituted with C<sub>1-6</sub> alkyl; amido; or (lower alkyl)amide;
- (iv) C<sub>6</sub> or C<sub>10</sub> aryl or C<sub>7-16</sub> aralkyl, all optionally substituted with C<sub>1-6</sub> alkyl, hydroxy, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted

with C<sub>1-6</sub> alkyl; or

(v) Het or (lower alkyl)-Het, both optionally substituted with C<sub>1-6</sub> alkyl, hydroxy, amido, (lower alkyl) amide, or amino optionally mono- or di-substituted with C<sub>1-6</sub> alkyl;

5 R<sub>5</sub> is H or C<sub>1-6</sub> alkyl;

with the proviso that when B is a carboxyl derivative, an amide derivative or a thioamide derivative, R<sub>4</sub> is not a cycloalkoxy;

Y is H or C<sub>1-6</sub> alkyl;

R<sup>3</sup> is C<sub>1-8</sub> alkyl, C<sub>3-7</sub> cycloalkyl, or C<sub>4-10</sub> alkylcycloalkyl, all optionally substituted with  
10 hydroxy, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> thioalkyl, amido, (lower alkyl)amido, C<sub>6</sub> or C<sub>10</sub> aryl, or C<sub>7-16</sub> aralkyl;

R<sup>2</sup> is CH<sub>2</sub>-R<sub>20</sub>, NH-R<sub>20</sub>, O-R<sub>20</sub> or S-R<sub>20</sub>, wherein R<sub>20</sub> is quinolyl or (lower alkyl)quinolyl, both optionally mono-, di- or tri-substituted with R<sub>21</sub>,

wherein each R<sub>21</sub> is independently C<sub>1-6</sub> alkyl; C<sub>1-6</sub> alkoxy; lower thioalkyl; sulfonyl;

15 NO<sub>2</sub>; OH; SH; halo; haloalkyl; amino optionally mono- or di-substituted with C<sub>1-6</sub> alkyl, C<sub>6</sub> or C<sub>10</sub> aryl, C<sub>7-14</sub> aralkyl, Het or (lower alkyl)-Het; amido optionally mono-substituted with C<sub>1-6</sub> alkyl, C<sub>6</sub> or C<sub>10</sub> aryl, C<sub>7-14</sub> aralkyl, Het or (lower alkyl)-Het; carboxyl; carboxy(lower alkyl); C<sub>6</sub> or C<sub>10</sub> aryl, C<sub>7-14</sub> aralkyl or Het, said aryl, aralkyl or Het being optionally substituted with R<sub>22</sub>;

20 wherein R<sub>22</sub> is C<sub>1-6</sub> alkyl; C<sub>3-7</sub> cycloalkyl; C<sub>1-6</sub> alkoxy; amino optionally mono- or di-substituted with C<sub>1-6</sub> alkyl or C<sub>3-7</sub>cycloalkyl; sulfonyl; (lower alkyl)sulfonyl; NO<sub>2</sub>; OH; SH; halo; haloalkyl; carboxyl; amide; (lower alkyl)amide; or Het optionally substituted with C<sub>1-6</sub> alkyl;

R<sup>1</sup> is H; C<sub>1-6</sub> alkyl, C<sub>3-7</sub> cycloalkyl, C<sub>2-6</sub> alkenyl, or C<sub>2-6</sub> alkynyl, all optionally substituted  
25 with halogen;  
or a tautomer thereof.

(b) about 0.1 to 10% by weight of a pharmaceutically acceptable amine or a mixture of pharmaceutically acceptable amines; and

30 (c) one or more pharmaceutically acceptable oils, carriers or hydrophilic solvents;

and when (c) is one or more pharmaceutically acceptable oils, the pharmaceutical composition further comprises:

- (d) optionally one or more pharmaceutically acceptable hydrophilic solvents;
- 5 (e) optionally one or more pharmaceutically acceptable polymers;
- and
- (f) optionally one or more pharmaceutically acceptable surfactants;

and when (c) is one or more pharmaceutically acceptable carriers, the pharmaceutical composition further comprises:

- 10 (d) optionally one or more pharmaceutically acceptable surfactants.

2. A pharmaceutical composition according to claim 1, wherein the compound of formula (I) is present in an amount of from about 1% to 50% by weight.

15

3. A pharmaceutical composition according to claim 1 or 2, wherein the amine is present in an amount of from about 0.1% to 7% by weight.

4. A pharmaceutical composition according to any of the preceding claims, wherein  
20 the amine is a C<sub>1-6</sub> alkylamine, di-(C<sub>1-6</sub> alkyl)-amine or tri-(C<sub>1-6</sub> alkyl)-amine, wherein one or more alkyl groups thereof may be optionally substituted by one or more hydroxy groups, or the amine is C<sub>1-6</sub> alkylenediamine, a basic amino acid or choline hydroxide, or mixtures thereof.

25 5. A pharmaceutical composition according to any of the preceding claims, wherein the amine is selected from ethanolamine, diethanolamine, triethanolamine, tris(hydroxymethyl)aminomethane, ethylenediamine or dimethylaminoethanol, or mixtures thereof.

30 6. A pharmaceutical composition according to any of the preceding claims, wherein the one or more pharmaceutically acceptable oils, carriers or hydrophilic solvents are



present in an amount of from about 1% to 99% by weight.

7. A pharmaceutical composition according to any of the preceding claims, wherein the pharmaceutically acceptable oil is selected from: medium or long chain mono-, di- or triglycerides, water insoluble vitamins, fatty acids and mixtures thereof.

8. A pharmaceutical composition according to any of the preceding claims, wherein the pharmaceutically acceptable oil is selected from: mono-, di- or triglycerides of caprylic fatty acids; mono-, di- or triglycerides of capric fatty acids; oleic acid, and mixtures thereof.

9. A pharmaceutical composition according to any of the preceding claims, wherein the pharmaceutically acceptable carrier is selected from a pharmaceutically acceptable polymer and a pharmaceutically acceptable urea.

10. A pharmaceutical composition according to any of the preceding claims, wherein the pharmaceutically acceptable carrier is selected from polyethylene glycols, polyvinylpyrrolidones, polyvinylalcohols, cellulose derivatives, polyacrylates, polymethacrylates, polyglycolized glycerides, ureas, sugars, polyols, and mixtures thereof.

11. A pharmaceutical composition according to any of the preceding claims, wherein the pharmaceutically acceptable hydrophilic solvent is selected from propylene glycol, polypropylene glycol, polyethylene glycol, glycerol, ethanol, dimethyl isosorbide, glycofurol, propylene carbonate, dimethyl acetamide, water, or mixtures thereof.

12. A pharmaceutical composition according to any of the preceding claims, wherein the pharmaceutically acceptable hydrophilic solvent is selected from propylene glycol, polyethylene glycol, ethanol, water, and mixtures thereof.

13. A pharmaceutical composition according to any of the preceding claims, wherein

the pharmaceutically acceptable polymer is present in an amount of up to about 50% by weight.

14. A pharmaceutical composition according to any of the preceding claims, wherein  
5 the pharmaceutically acceptable polymer is selected from polyethylene glycols, polyvinylpyrrolidones, polyvinylalcohols, cellulose derivatives, polyacrylates, polymethacrylates, sugars, polyols, and mixtures thereof.

15. A pharmaceutical composition according to any of the preceding claims, wherein  
10 the pharmaceutically acceptable surfactant is present in an amount of up to about 70% by weight.

16. A pharmaceutical composition according to any of the preceding claims, wherein  
the pharmaceutically acceptable surfactant is selected from d-alpha tocopheryl  
15 polyethylene glycol 1000 succinate, polyoxyl castor oils, polysorbates, peglicol 6-oleate, polyoxyethylene stearates, polyglycolized glycerides or poloxamers, or sodium lauryl sulfate and mixtures thereof.

17. A pharmaceutical composition according to any of the preceding claims, wherein  
20 the pharmaceutically acceptable surfactant is selected from d-alpha tocopheryl polyethylene glycol 1000 succinate, polyoxyl 40 hydrogenated castor oil, polyoxyl 35 castor oil, polyoxypropylene-polyoxyethylene block copolymer, or sodium lauryl sulfate, and mixtures thereof.

25 18. A pharmaceutical composition according to any of the preceding claims, further comprising one or more pharmaceutically acceptable bases.

19. A pharmaceutical composition according to claim 18, wherein the  
pharmaceutically acceptable bases is selected from sodium hydroxide, potassium  
30 hydroxide, sodium hydrogen carbonate, aluminum hydroxide, magnesium hydroxide, and magnesium aluminum hydroxide.

20. A pharmaceutical composition according to claim 1, comprising:

(A)

- 5 (a) about 5% to 15% by weight of a compound of formula (I);  
(b) about 0.5% to 5% by weight of tris(hydroxymethyl)aminomethane; and  
(c) about 80% to 90% by weight of a mixture of propylene glycol, ethanol and water;

or

(B)

- 10 (a) about 10% to 20% by weight of a compound of formula (I);  
(b) about 0.1% to 5% by weight of tris(hydroxymethyl)aminomethane;  
(c) about 20% to 70% by weight of a mono- or diglyceride of caprylic fatty acid or a mono- or diglyceride of capric fatty acid, or mixtures thereof;  
(d) about 10% to 30% by weight of a mixture of propylene glycol, ethanol and  
15 optionally water;  
(e) optionally about 1% to 20% by weight of polyethylene glycol or polyvinylpyrrolidone; and  
(f) about 20% to 50% by weight of d-alpha tocopheryl polyethylene glycol 1000 succinate or polyoxyl 35 castor oil;

20 or

(C)

- (a) about 10% to 20% by weight of a compound of formula (I);  
(b) about 0.1% to 5% by weight of tris(hydroxymethyl)aminomethane;  
25 (c) about 60% to 80% by weight of polyethylene glycol, polyvinylpyrrolidone, lactose or a mixture thereof; and  
(d) about 1% to 20% by weight of d-alpha tocopheryl polyethylene glycol, 1000 succinate, polyoxypropylene-polyoxyethylene block copolymer or sodium lauryl sulfate.

30

21. A pharmaceutical composition according to claim 20, said composition further

comprising about 0.1 to 5% by weight of sodium hydroxide.

22. A pharmaceutical composition according to any of the preceding claims, wherein in the compound of formula (I):


5 **B** is a carboxyl derivative of formula  $R_4-O-C(O)-$ , wherein  $R_4$  is

$C_{3-7}$  cycloalkyl, or  $C_{4-10}$  alkylcycloalkyl, all optionally substituted with carboxyl,  $(C_{1-6}$  alkoxy)carbonyl, amido, (lower alkyl)amide, or amino optionally mono- or di-substituted with  $C_{1-6}$  alkyl;

**Y** is H or methyl;


10  $R^3$  is  $C_{1-8}$  alkyl;

$R^2$  is:



wherein  $R_{22B}$  is  $C_{1-6}$  alkyl; amino optionally mono- or di-substituted with  $C_{1-6}$ alkyl or  $C_{3-7}$  cycloalkyl; (lower alkyl)amide; or amido; and  $R_{21B}$  is  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy, amino,

15 di(lower alkyl)amino, (lower alkyl)amide,  $NO_2$ , OH, halo, trifluoromethyl, or carboxyl; and



**P1** is

and  $R^1$  is ethyl, vinyl, cyclopropyl, 1 or 2-bromoethyl or 1 or 2-bromovinyl;

20 23. A pharmaceutical composition according to any of the preceding claims, in the form of a fluid dosage form selected from a hard shell or softgel capsule or in the form of a solid dosage form selected from a powder, a tablet or a capsule.

24. A pharmaceutical composition according to any of the preceding claims, further comprising one or more antioxidants.

25. A pharmaceutical composition according to claim 24, wherein the antioxidant is present in an amount of about 0.01 to 1% by weight.

26. A pharmaceutical composition according to claim 24, wherein the antioxidant is selected from ascorbic acid, sulfatide salts, citric acid, propyl gallate, dl- $\alpha$ -tocopherol, ascorbyl palmitate, BHT or BHA.

10

27. A method of manufacturing a pharmaceutical composition according to any of the preceding claims, said method comprising:

- 15 (A) (a) dissolving the amine(s) in the one or more pharmaceutically acceptable solvents; (b) adding the compound of formula (I) to the solution obtained in step (a) and mixing; or
- (B) (a) mixing together the pharmaceutically acceptable oil(s), surfactant(s) and solvent(s); (b) dissolving the pharmaceutically acceptable amine(s) in the mixture obtained in step (a); (c) optionally heating the mixture obtained in step (b) if necessary to sufficiently melt one or more of the components of the mixture; (d) 20 adding the compound of formula (I) to the mixture obtained in steps (b) or (c) and mixing; or
- (C) (a) dissolving the pharmaceutically acceptable amine(s), the pharmaceutically acceptable carrier(s) and optionally the pharmaceutically acceptable surfactant(s) in a suitable hydrophilic solvent; (b) adding the compound of formula (I) to the solution obtained in step (a) and mixing to dissolve the compound of formula (I); 25 (c) evaporating the hydrophilic solvent to cause co-precipitation of the compound of formula (I), the amine(s), the carrier(s) and the optional surfactant(s); or
- (D) (a) mixing the pharmaceutically acceptable carrier(s) and the optional surfactant(s) and heating the resulting mixture to sufficiently melt the carrier(s) and surfactant(s); (b) adding the pharmaceutically acceptable amine(s) and the 30 compound of formula (I) to the mixture obtained in step (a) and mixing; or

- (E) (a) mixing the compound of formula (I), the pharmaceutically acceptable amine(s), the pharmaceutically acceptable carrier(s) and optionally the pharmaceutically acceptable surfactant(s) to form a blend, and (b) optionally adding a lubricant to the blend; or
- 5 (F) (a) mixing the compound of formula (I), the pharmaceutically acceptable amine(s), the pharmaceutically acceptable carrier(s) and optionally the pharmaceutically acceptable surfactant(s) while adding water or another hydrophilic solvent(s) to the mixture to obtain a paste; (b) drying the paste of step (a) to a sufficient level of dryness; and (c) passing the dried paste through a
- 10 screen.
28. A method of inhibiting the replication of hepatitis C virus by exposing the virus to a hepatitis C viral NS3 protease inhibiting amount of the composition according to any one of claims 1 to 26.
- 15
29. A method of treating a hepatitis C viral infection in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of the composition according to any one of claims 1 to 26.
- 20 30. Use of a composition according to any one of claims 1 to 26 for the preparation of a medicament for the treatment or prevention of hepatitis C viral infection.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 03/22434

A. CLASSIFICATION OF SUBJECT MATTER  
 IPC 7 A61K47/16 A61K31/4709 A61P31/14

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, MEDLINE, EMBASE, BIOSIS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>US 6 323 180 B1 (GOUDREAU NATHALIE ET AL)            27 November 2001 (2001-11-27)            cited in the application            abstract            column 8, line 51 - line 57            claims 1-79            &amp; WO 00 09543 A (BOEHRINGER INGELHEIM            (CANADA) LTD)            24 February 2000 (2000-02-24)            abstract            page 12, line 4 - line 8            claims 1-87</p> <p style="text-align: center;">--- -/--</p>	1-30



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the International filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the International filing date but later than the priority date claimed

\*T\* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*G\* document member of the same patent family

Date of the actual completion of the International search

21 November 2003

Date of mailing of the International search report

05/12/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax (+31-70) 340-3016

Authorized officer

Taylor, G.M.

## INTERNATIONAL SEARCH REPORT

Internatic.....pplication No

PCT/US 03/22434

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 07733 A (BOEHRINGER INGELHEIM CA LTD ;RANCOURT JEAN (CA); SIMONEAU BRUNO (C) 18 February 1999 (1999-02-18) abstract page 1, line 5 - line 11 claims 1-45 -----	1-30
E	WO 03 066103 A (BOEHRINGER INGELHEIM PHARMA) 14 August 2003 (2003-08-14) abstract page 1, line 5 - line 8 Formulation Examples page 53, line 11 -page 54 claims 1-35 figures 1,2 -----	1-30
A	"Remington's Pharmaceutical Sciences" 1975 , MACK PUBLISHING COMPANY , EASTON, PA, USA XP002262427 "Tromethamine" page 773 -----	1-30



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 03/22434

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  

Although claims 28 and 29 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 03/22434

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 6323180	B1	27-11-2001	US 6534523 B1 18-03-2003
			US 6268207 B1 31-07-2001
			US 6329379 B1 11-12-2001
			US 6329417 B1 11-12-2001
			US 2002016442 A1 07-02-2002
			US 2002037998 A1 28-03-2002
			AU 5273199 A 06-03-2000
			BG 105232 A 30-11-2001
			BR 9913646 A 05-06-2001
			CA 2338946 A1 24-02-2000
			WO 0009543 A2 24-02-2000
			CN 1323316 T 21-11-2001
			CZ 20010516 A3 15-08-2001
			EE 200100081 A 15-08-2002
			EP 1105413 A2 13-06-2001
			HR 20010102 A1 28-02-2002
			HU 0105144 A2 29-04-2002
			JP 2002522554 T 23-07-2002
			NO 20010683 A 02-04-2001
			PL 346626 A1 25-02-2002
			SK 2062001 A3 08-10-2001
			TR 200100432 T2 21-09-2001
			TR 200200129 T2 21-06-2002
WO 9907733	A	18-02-1999	AU 757783 B2 06-03-2003
			AU 8795698 A 01-03-1999
			WO 9907733 A2 18-02-1999
			EP 1003775 A2 31-05-2000
			HU 0004853 A2 28-05-2001
			JP 2001512743 T 28-08-2001
			NZ 503262 A 25-10-2002
WO 03066103	A	14-08-2003	WO 03066103 A1 14-08-2003
			US 2003195228 A1 16-10-2003